

REC'D 15 DEC 2004

WIPO

PCT

PA 1236460

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

October 18, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/507,996

FILING DATE: October 02, 2003

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS




M. K. HAWKINS
Certifying Officer

BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. **EF195551091 US**

INVENTOR(S)					
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)	
Herman Augustinus		DE KOCK		B-2370 Arendonk, Belgium	
Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number	000027777		Place Customer Number Bar Code Label here		
OR Type Customer Number here					
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City			State	ZIP	
Country			Telephone	Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification	Number of Pages	63	<input type="checkbox"/> CD(s), Number		
<input type="checkbox"/> Drawing(s)	Number of Sheets		<input type="checkbox"/> Other (specify)		
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.			FILING FEE AMOUNT (\$)		
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:			10-0750/TIP0054/11/ET		
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.			\$160.00		
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:					

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME **JESUS JUANOS 2 TIMONEDA**TELEPHONE **732 5241513**

Date

02/07/03

REGISTRATION NO.

43332

(If appropriate)

Docket Number:

TIP0051**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

22151 U.S. PTO
60/507996

100203

PROVISIONAL APPLICATION COVER SHEET

Additional Page

PTO/SB/16 (05-03)

Approved for use through 4/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number **TIP0051**

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle (if any))	Family or Surname	Residence (City and either State or Foreign Country)
Walter Ferdinand Maria	FILLIERS	B-2531 Vremde, Belgium
Wim Albert Alex	AELTERMAN	B-2275 Gierle, Belgium

[Page 2 of 2]

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Herman Augustinus DE KOCK, *et al.*

Serial No.:

Art Unit:

Filed : October 2, 2003

Examiner:

For : METHODS FOR THE PREPARATION OF BENZOXAZOLE
SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF

I hereby certify that this correspondence is being deposited with the

United States Postal Service as Express Mail No. EF195551091 U.S. in an envelope addressed
to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on

October 2, 2003

(Date of Deposit)

Jesús Juanós i Timoneda

(Name of applicant, assignee, or Registered Representative)



(Signature)

October 2, 2003

(Date of Signature)

Commissioner For Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed find:

- Provisional Application for Patent Cover Sheet
- Application – 63 pages
- Express Mail Certificate

In the event of any non-payment of a required fee, the Commissioner is authorized to charge or credit Deposit Account No. 10-0750/TIP0051/JJiT in the name of Johnson & Johnson as required to correct the error.

Respectfully submitted,



Jesús Juanós i Timoneda
Reg. No. 43,332
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1513
DATE: October 2, 2003

DOCKET NO. TIP 0051

IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

Applicant: Herman Augustinus DE KOCK, et al.

For : METHODS FOR THE PREPARATION OF BENZOXAZOLE
SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF

Express Mail Certificate

"Express Mail" mailing number: EF195551091US


Date of Deposit: October 2, 2003

I hereby certify that this complete provisional application, including specification pages and claims, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

A Combined Declaration and Power of Attorney will be submitted to the United States Patent and Trademark Office upon receipt of the U.S. Serial Number for this patent application.

Laurie A. Phillips

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)

METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF :

Field of the invention

- 5 The present invention relates to methods for the preparation of benzoxazole sulfonamide compounds as well as novel intermediates for use in said method. More in particular the invention relates to methods for the preparation of 2-amino-benzoxazole sulfonamide compounds which make use of 2-mercapto-benzoxazole sulfonamide intermediates, more in particular methods employing the intermediate 1-Benzyl-2-
10 hydroxy-3-[isobutyl-(2-methylsulfanyl-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic ester, and to methods amenable to industrial scaling up. Said benzoxazole sulfonamide compounds are particularly useful as HIV protease inhibitors.

Background

- 15 The virus causing the acquired immunodeficiency syndrome (AIDS) is known by different names, including T-lymphocyte virus III (HTLV-III) or lymphadenopathy-associated virus (LAV) or AIDS-related virus (ARV) or human immunodeficiency virus (HIV). Up until now, two distinct families have been identified, i.e. HIV-1 and HIV-2. Hereinafter, HIV will be used to generically denote these viruses.


20

- One of the critical pathways in a retroviral life cycle is the processing of polyprotein precursors by retroviral protease. For instance, during the replication cycle of the HIV virus, gag and gag-pol gene transcription products are translated as proteins, which are subsequently processed by a virally encoded protease to yield viral enzymes and
25 structural proteins of the virus core. Most commonly, the gag precursor proteins are processed into the core proteins and the pol precursor proteins are processed into the viral enzymes, e.g., reverse transcriptase and retroviral protease. Correct processing of the precursor proteins by the retroviral protease is necessary for the assembly of infectious virions, thus making the retroviral protease an attractive target for antiviral
30 therapy. In particular for HIV treatment, the HIV protease is an attractive target.

- Several protease inhibitors are on the market or are being developed. Benzoxazole sulfonamide HIV protease inhibitors, for example 2-amino-benzoxazole sulfonamides, have been described to have favourable pharmacological and pharmacokinetic
35 properties against wild-type and mutant HIV virus. The particular core structure, 2-amino-benzoxazole sulfonamide, can generally be prepared using procedures analogous to those procedures described in WO 95/06030, WO 96/22287, WO 96/28418, WO 96/28463, WO 96/28464, WO 96/28465 and WO 97/18205. In

particular, methods for preparing 2-amino-benzoxazole sulfonamides have been described in WO 02/092595. However, such methods are in general complex, experiencing a burdensome halosulfonation, and providing insufficient yields for commercial purposes. Therefore, there is a need in the art for improved methods for preparing 2-amino benzoxazole sulfonamide protease inhibitors, which overcome at least some of the above-mentioned problems.

The present invention provides improved methods for preparing a retrovirus protease inhibitor, in particular for preparing 2-amino-benzoxazole sulfonamides. In particular, the present invention provides novel intermediate compounds of formula (6), 2-mercapto-benzoxazole sulfonamides, which are useful as precursors in the synthesis of 2-amino-benzoxazole sulfonamides.




(6)

The use of compounds of formula (6) as intermediates allow the production of a broad and diverse range of 2-amino-benzoxazole sulfonamides, thus providing a broad range of HIV protease inhibitors starting from a single family of intermediates. Also, as exemplified below, the present method presents a convenient sulfonation and is consequently easy and cost-effective. Furthermore, another advantage of the present method is that acceptable yields for commercial purposes of 2-amino-benzoxazole sulfonamide protease inhibitors can be obtained. The present method has the further advantage of using commercially available starting material, such as a 2-mercapto-benzoxazole. The reagents further used in said method are safe and available in bulk. Furthermore, each step of said method provides with the desired compound in good yield. Moreover, each step of said method can be performed stereoselectively, which allows the synthesis of pure stereoisomeric forms of said compounds when using, where appropriate, optically pure starting material and reagents. Thus, the methods according to the present invention are amenable for industrial scaling up.

Other objects and advantages of the present invention will become apparent from the following detailed description taken in conjunction with the accompanying examples.

Detailed description of the invention

The present invention involves methods for the synthesis of 2-amino-benzoxazole sulfonamides through the intermediates of formula (6)



(6)

and salts, stereoisomeric forms, and racemic mixtures thereof, wherein

PG represents a protecting group;

R₂ is hydrogen or C₁₋₆alkyl;


R₃ is C₃₋₇cycloalkyl, aryl, Het¹, Het², or C₁₋₆alkyl optionally substituted with C₃₋₇cycloalkyl, aryl, Het¹, or Het²; wherein each C₃₋₇cycloalkyl, aryl, Het¹, and Het² may be optionally substituted with one or more groups selected from oxo, C₁₋₆alkyloxy, C₁₋₆alkyl, C₁₋₆alkylsulfonyl, aminosulfonyl, amino, C₁₋₆alkylcarbonylamino, hydroxyC₁₋₆alkyl, cyano, C₁₋₆alkyloxycarbonyl, aminocarbonyl, halogen or trifluoromethyl, wherein each amino maybe mono- or disubstitued with C₁₋₆alkyl;

R₄ is selected from the group comprising hydrogen, C₁₋₄alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, or C₁₋₆alkyl optionally substituted with one or more substituents each independently selected from aryl, Het¹, Het², C₃₋₇cycloalkyl, C₁₋₄alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, C₁₋₄alkyl-S(=O)_t, hydroxy, cyano, halogen and amino optionally mono- or disubstitued where the substituents are each independently selected from C₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, Het¹, Het², Het¹C₁₋₄alkyl and Het²C₁₋₄alkyl;

t is zero, one or two; and

E represents an electrophilic moiety.


Intermediates of formula (6) may be prepared starting from compounds of formula (2),



(2)


wherein E is as described above;

transforming said intermediates of formula (2) into sulfonyl derivatives of formula (3),




(3)

wherein LG represents a leaving group;
subsequently reacting said sulfonyl derivatives with compounds of formula (5),



(5)


wherein PG, R₂, R₃, and R₄ are as described above;
thus obtaining intermediate compounds of formula (6).



(6)


In a preferred embodiment, the present invention relates to a method for the synthesis
of 2-amino-benzoxazole sulfonamides of formula (9), which comprises the steps of:

- a) coupling an electrophilic moiety (E) to a 2-mercapto-benzoxazole of formula (1)




(1)

resulting into a compound of formula (2), wherein E is as described above;




(2)


- b) reacting said compound of formula (2) with a sulfonation agent and introducing a
leaving group (LG), resulting in an intermediate of formula (3), wherein LG is as
described above;




- c) coupling said intermediate of formula (3) with a compound of formula (5), wherein
 5 **PG, R₂, R₃, and R₄** are as described above;



obtaining the intermediate of formula (6),



- d) followed by an amination of compound of formula (6) to obtain 2-amino-
 benzoxazole sulfonamides of compound of formula (7), wherein



R₆ is hydrogen, hydroxy, C₁₋₆alkyl, Het¹C₁₋₆alkyl, Het²C₁₋₆alkyl, aminoC₁₋₆alkyl
 whereby the amino group may optionally be mono- or di-substituted with C₁₋₄alkyl;

20 **R₈** is hydrogen, C₁₋₆alkyl, or -A-R₇;

A is C₁₋₆alkanediyl, -C(=O)-, -C(=S)-, -S(=O)₂-, C₁₋₆alkanediyl-C(=O)-,
 C₁₋₆alkanediyl-C(=S)- or C₁₋₆alkanediyl-S(=O)₂-; whereby the point of attachment to
 the nitrogen atom is the C₁₋₆alkanediyl group in those moieties containing said group;


R₇ is C₁₋₆alkyloxy, Het¹, Het¹oxy, Het², Het²oxy, aryl, aryloxy, C₃₋₇cycloalkyl,
 25 or optionally mono- or disubstituted amino; and

- in case -A- is other than C₁₋₆alkanediyl then R₇ may also be C₁₋₆alkyl, Het¹C₁₋₄alkyl, Het¹oxyC₁₋₄alkyl, Het²C₁₋₄alkyl, Het²oxyC₁₋₄alkyl, arylC₁₋₄alkyl, aryloxy-C₁₋₄alkyl or amino-C₁₋₄alkyl; whereby each of the amino groups in the definition of R₇ may optionally be substituted with one or more substituents selected from C₁₋₄alkyl, C₁₋₄alkylcarbonyl, C₁₋₄alkyloxycarbonyl, aryl, arylcarbonyl, aryloxycarbonyl, Het¹, Het², arylC₁₋₄alkyl, Het¹-C₁₋₄alkyl or Het²C₁₋₄alkyl; and.

-A-R₇ may also be hydroxyC₁₋₆alkyl; and


- R₆ and -A-R₇ taken together with the nitrogen atom to which they are attached may also form Het¹ or Het²;

- e) deprotecting compound of formula (7) to obtain 2-amino-benzoxazole sulfonamides of compound of formula (8),




(8)

- f) coupling a radical of formula R₁-L- to obtain the corresponding 2-amino-benzoxazole sulfonamide protease inhibitor of formula (9),



(9)

- wherein R₁ is selected from the group comprising hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, arylC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, aryl, Het¹, Het¹C₁₋₆alkyl, Het², Het²C₁₋₆alkyl; and R₁ may also be a radical of formula (10)



(10)

wherein R_9 , R_{10a} and R_{10b} are, each independently, hydrogen, C_{1-4} alkyloxy-carbonyl, carboxyl, aminocarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyl, C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{1-4} alkyl optionally substituted with aryl, Het^1 , Het^2 , C_{3-7} cycloalkyl, C_{1-4} alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyl, aminosulfonyl, C_{1-4} alkylS(O)_n, hydroxy, cyano, halogen or amino optionally mono- or disubstituted where the substituents are each independently selected from C_{1-4} alkyl, aryl, aryl C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, Het^1 , Het^2 , Het^1C_{1-4} alkyl and Het^2C_{1-4} alkyl; whereby R_9 , R_{10a} and the carbon atoms to which they are attached may also form a C_{3-7} cycloalkyl radical;

when L is $-O-C_{1-6}$ alkanediyl-C(=O)- or $-NR_{12}-C_{1-6}$ alkanediyl-C(=O)-, then R_9 may also be oxo;

R_{11a} is selected from the group comprising hydrogen, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, aryl, aminocarbonyl optionally mono- or disubstituted, amino C_{1-4} alkylcarbonyloxy optionally mono- or disubstituted, C_{1-4} alkyloxycarbonyl, aryloxy carbonyl, Het^1 oxy carbonyl, Het^2 oxy carbonyl, aryloxy carbonyl C_{1-4} alkyl, aryl C_{1-4} alkyloxycarbonyl, C_{1-4} alkylcarbonyl, C_{3-7} cycloalkylcarbonyl, C_{3-7} cycloalkyl- C_{1-4} alkyloxycarbonyl, C_{3-7} cycloalkylcarbonyloxy, carboxyl C_{1-4} alkylcarbonyloxy, C_{1-4} alkylcarbonyloxy, aryl C_{1-4} alkylcarbonyloxy, arylcarbonyloxy, aryloxy carbonyloxy, Het^1 carbonyl, Het^1 carbonyloxy, Het^1C_{1-4} alkyloxycarbonyl, Het^2 carbonyloxy, Het^2C_{1-4} alkylcarbonyloxy, Het^2C_{1-4} alkyloxycarbonyloxy or C_{1-4} alkyl optionally substituted with aryl, aryloxy, Het^2 or hydroxy; wherein the substituents on the amino groups are each independently selected from C_{1-4} alkyl, aryl, aryl C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl

C_{1-4} alkyl, Het^1 , Het^2 , Het^1C_{1-4} alkyl and Het^2C_{1-4} alkyl;

R_{11b} is selected from the group comprising hydrogen, C_{3-7} cycloalkyl, C_{2-6} alkenyl,

C_{2-6} alkynyl, aryl, Het^1 , Het^2 or C_{1-4} alkyl optionally substituted with halogen, hydroxy, C_{1-4} alkylS(=O)_n, aryl, C_{3-7} cycloalkyl, Het^1 , Het^2 , amino optionally mono- or disubstituted where the substituents are each independently selected from C_{1-4} alkyl, aryl, aryl C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, Het^1 , Het^2 , Het^1C_{1-4} alkyl and Het^2C_{1-4} alkyl;

whereby R_{11b} may be linked to the remainder of the molecule via a sulfonyl group;

L is selected from the group comprising $-C(=O)-$, $-O-C(=O)-$, $-NR_{12}-C(=O)-$, $-O-C_{1-6}$ alkanediyl-C(=O)-, $-NR_{12}-C_{1-6}$ alkanediyl-C(=O)-, $-S(=O)_2-$, $-O-S(=O)_2-$, $-NR_{12}-S(=O)_2$ whereby either the C(=O) group or the S(=O)₂ group is attached to the

NR₂ moiety; whereby the C₁₋₆alkanediyl moiety is optionally substituted with a substituent selected from hydroxy, aryl, Het¹, and Het²; and


R₁₂ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, arylC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, aryl, Het¹, Het¹C₁₋₆alkyl, Het², Het²C₁₋₆alkyl.

5

In a more preferred embodiment, the present invention relates to a method for the synthesis of 2-amino-benzoxazole sulfonamides of formula (9'), which comprises the steps of:

a) alkylating a 2-mercapto-benzoxazole of formula (1)


10



(1)

resulting into a 2-alkylthio-benzoxazole of formula (2), wherein E is C₁₋₆alkyl, preferably methyl;


15



(2)


b) reacting said 2-alkylthio-benzoxazole of formula (2) with a sulfonation agent and introducing a leaving group (LG) resulting in an intermediate of formula (3),

20



(3)


c) coupling said intermediate of formula (3) with a compound of formula (5'), wherein R₂ is hydrogen, R₃ is benzyl, and R₄ is isobutyl;




(5')

25

thus obtaining the intermediate of formula (6'),




- 5 d) followed by an amination of compound of formula (6') to obtain 2-amino-benzoxazole sulfonamides of compound of formula (7'),



- 10 wherein R₆ and R₈ are as described above;


e) deprotecting compound of formula (7') to obtain 2-amino-benzoxazole sulfonamides of compound of formula (8'),




15

f) coupling a radical of formula R₁-L- for obtaining the corresponding 2-amino-benzoxazole sulfonamide protease inhibitor of formula (9'),

wherein R₁, and L are as described above.




In a more preferred embodiment, said R_1 is a Het¹, or a Het¹C₁₋₆alkyl, L is -O-C(=O)-, and R_6 is hydrogen as indicated in formula (9'') below.




Compound of formula (1)

Compound of formula (1), 2-mercapto-benzoxazole, may be directly purchased from commercially available sources, or may be prepared with procedures available in the art.



Compounds of formula (2)

The 2-mercaptobenzoxazole, compound of formula (1), is subjected to a reaction with a suitable reagent to introduce an electrophilic moiety (E) which together with the -S-atom form a thiol-based leaving group (-S-E).



Said reagent is any material capable of providing to the reaction an electrophilic moiety (E) capable of reacting with the sulfur atom of the thiol (or mercapto or sulfhydryl) of the compound of formula (1) to form a new carbon sulfur bond thereby creating a thioether linkage, thus resulting in a thiol-based leaving group (-S-E).

The term "leaving group" is an atom or group of atoms which is displaceable upon reaction with an appropriate nucleophile. Such leaving groups are well known in the art. The term "electrophilic moiety" is so used to describe the electron deficient center moiety of an electrophile.

Preferred electrophiles for introducing electrophilic moieties are the alkylating agents which include, but are not limited to, C₁₋₆alkyl halides such as methyl iodide, ethyl iodide, n-propyl iodide, butyl iodide, methyl bromide, ethyl bromide, n-propyl bromide, and pentyl bromide; cycloC₃₋₇alkyl halides such as cyclohexyl bromide, and cyclopentylmethyl bromide; aryl-C₁₋₄alkyl halides such as 2-bromobenzyl bromide, 2-bromobenzyl chloride and the like; di-C₁₋₆alkyl sulfates such as dimethyl sulfate, diethyl sulfate, and di-n-propyl sulfate;

C₁₋₆alkylsulfonates such as ethyl methanesulfonate, n-propyl methanesulfonate; arylsulfonates; C₁₋₆alkyltoluenesulfonates such as methyl-p-toluenesulfonate; and the like. Other examples of electrophiles include acetic anhydride, trimethylacetyl chloride, butanoic anhydride, methyl succinoyl chloride, t-butyl succinoyl chloride, diethyldicarbonate, dimethyldicarbonate, benzoyl chloride, acetylacetoxy derivatives, haloacetamide derivatives, and the like. Other electrophiles include derivatives of epoxides, oxetanes, aziridines, azetidines, episulfides, maleimides, 2-oxazolin-5-ones, N-hydroxysuccinimides, mesylates, tosylates, nosylates, brosylates, isothiocyanates, electron-deficient aromatic rings, such as nitro-substituted pyrimidine rings, etc. Most preferred electrophiles are C₁₋₆alkylating agents. A particular suitable C₁₋₆alkylating agent is methyl iodide which can be dissolved in customary solvents. Alternatively, ethyltosylate may be used as C₁₋₆alkylating agent.

In still other embodiments, the electrophile may be a group wherein, upon reaction with the nucleophilic S, an addition reaction takes place, leading to the formation of a covalent bond, for example with electron-deficient alkenes, such as α,β -unsaturated carbonyls, vinylsulfones.

The introduction of an electrophilic moiety (E) is carried out in the presence of conventional non-nucleophilic inorganic or organic bases. These include, for example, the hydrides, hydroxides, amides, alcoholates, acetates, carbonates, or hydrogen carbonates of alkaline earth metals or alkali metal hydrides such as, for example,

sodium hydride, potassium hydride or calcium hydride, and metal amides, such as sodium amide, potassium amide, lithium diisopropylamide or potassium hexamethyl-
disilazide, and metal alkanes such as sodium methylate, sodium ethylate, potassium
tert-butyrate, sodium hydroxide, potassium hydroxide, ammonium hydroxide, sodium
5 acetate, potassium acetate, calcium acetate, ammonium acetate, sodium carbonate,
sodium bicarbonate, potassium carbonate, potassium bicarbonate, cesium carbonate,
potassium hydrogen carbonate, sodium hydrogen carbonate, or ammonium carbonate,
and also basic organic nitrogen compounds such as, trialkylamines, like trimethyl-
amine, triethylamine, tributylamine, N,N-dimethylaniline, N,N-dimethyl-benzylamine,
10 N,N-diisopropylethylamine, pyridine, 1,4-diazabicyclo[2.2.2]-octane (DABCO),
1,5-diazabicyclo[4.3.0]-non-5-ene (DBN), or 1,8-diazabicyclo[5.4.0]-undec-7-ene
(DBU), or an excess of an appropriate piperidine compound may be used. The base is
preferably potassium carbonate, sodium carbonate, a sodium C₁₋₆alkoxide (e.g. sodium
methoxide, sodium ethoxide, etc.), 1,1,3,3-tetramethylguanidine, sodium hydride,
15 triethylamine and the like.

Suitable solvents for use in the introduction of an electrophilic moiety (E) include any
one which does not disturb the reaction, such as aliphatic, alicyclic or aromatic,
optionally halogenated hydrocarbons such as, for example, benzene, toluene, xylene,
20 chlorobenzene, dichlorobenzene, petroleum ether, hexane, cyclohexane, dichloro-
methane, chloroform, tetrachloromethane; ethers such as diethyl ether, diisopropyl
ether, dimethoxyethane, dioxane, tetrahydrofuran or ethylene glycol dimethyl ether or
ethylene glycol diethyl ether; ketones such as acetone, butanone, or methyl isobutyl
ketone; nitriles such as acetonitrile, propionitrile or benzonitrile; amides such as
25 N,N-dimethylformamide, N,N-dimethylacetamide, N-methylformanilide, N-methyl-
pyrrolidone, 1,3-dimethyl-2-imidazolidinone, or hexamethylphosphoric triamide; esters
such as methyl acetate or ethyl acetate; sulfoxides such as dimethyl sulfoxide; alcohols
such as methanol, ethanol, n- or i-propanol, n-, i-, s-, or t-butanol, ethylene glycol
monomethyl ether, ethylene glycol monoethyl ether, diethylene glycol monomethyl
30 ether, diethylene glycol monoethyl ether; or mixtures of these solvents. Preferably the
alkylation reaction is carried out in suitable aprotic solvents such as
dimethylformamide, acetonitrile, N-methylpyrrolidone, dimethylsulfoxide; ethers such
as tetrahydrofuran, 2-methyltetrahydrofuran, methyl t-butyl ether, diethyl ether,
dioxane; or esters such as ethyl acetate, or mixtures thereof.

35

In an embodiment, the introduction of an electrophilic moiety is exemplified with an
C₁₋₆alkylation reaction, which is suitably carried out at a temperature in the range from
about -30°C to about 180°C, preferably at a temperature of from about 10°C to about

70°C, more preferably at a temperature of from about 10°C to about 55° C, even more preferably at a temperature of from about 15° C to about 40° C, being room temperature most preferred.


- 5 The ratios of equivalents between the 2-mercaptobenzoxazole and the C₁₋₆alkylating agent may range from 1:1 to 1:5, respectively. Preferably, the ratio of equivalents between the 2-mercaptobenzoxazole and the C₁₋₆alkylating agent is from 1:1 to 1:2, more preferably the ratio is around 1:1.1. The ratios of equivalents between the 2-mercaptobenzoxazole and the base may range from 1:1 to 1:5, preferably the ratio of
10 equivalents ranges from 1:1.1 to 1:2, more preferably the ratio is around 1.3.

In an embodiment of the invention, the alkylation reaction is carried out in the presence of about 1.1 equivalents of methyl iodide, 1.3 equivalents of potassium carbonate and ethyl acetate, at ambient temperature, and stirring around 24 hours.

- 15 Alternative alkylating reactions encompass the use of Grignard reagents. Alkylating reactions are further described in Organic Synthesis, Vol. 31, pages 90-93, John Wiley & Sons, Inc., New York, New York.

20 **Compounds of formula (3)**

Sulfonyl derivatives of formula (3) are prepared as illustrated in following scheme.



- 25 Sulfonation of an intermediate of formula (2) may be performed by any conventionally known method. As used herein, the term "sulfonation" means methods of introducing a sulfonyl moiety -SO₂- into a molecule.

- Typical sulfonation agents are methanesulfonyl chloride, trifluoromethanesulfonyl chloride, trifluoromethanesulfonic anhydride, sulfonyl chloride, concentrated sulfuric acid (the sulfuric acid of about 70 wt % or higher is more preferable), sulfuric anhydride, fuming sulfuric acid, chlorosulfonic acid, sulfonated pyridine salt, sulfamic acid, amidosulfuric acid, fluorosulfuric acid, chlorosulfuric acid, sulfur trioxide, fuming sulfur, sulfuric acid, oleum, and sulfonation agents commonly employed in
30

electrophilic aromatic substitutions; which can be used singly or in combinations of two or more types.

5 The sulfonation is simultaneously or subsequently followed with the insertion of a leaving group (LG), to form the moiety LG-SO₂-. Alternatively, the sulfonation agent has the leaving group already incorporated. Agents for the insertion of a leaving group are halogenating reagents such as, phosphorous chloride, phosphoric chloride, thionyl chloride, phosphorus bromide, acetyl chloride, methyl chloroformate, methanesulfonyloxy chloride or an oxide.

10 Suitable leaving groups (LG) include alkoxy carbonyl groups such as ethoxy carbonyl; halogens such as iodine, bromine or chlorine, fluorine; substituted or unsubstituted saturated or unsaturated thiolates, such as thiomethyl or thiophenyl; substituted or unsubstituted saturated or unsaturated selenino compounds, such as phenyl selenide or
15 alkyl selenide; or -OR₂ where R₂ is a substituted or unsubstituted saturated or unsaturated alkyl group, e.g., a C₁₋₆ alkyl or alkenyl group such as methyl; a substituted or unsubstituted aliphatic or aromatic acyl group, e.g., a C₁₋₆ aliphatic acyl group such as acetyl and an aromatic acyl group such as benzoyl; a substituted or unsubstituted saturated or unsaturated alkoxy carbonyl group, such as methyl carbonate and phenyl
20 carbonate; substituted or unsubstituted sulphonyl imidazolidine; substituted or unsubstituted carbonyl imidazolidine; substituted or unsubstituted aliphatic or aromatic amino carbonyl group, such as phenyl carbamate; substituted or unsubstituted alkyl imidate group such as trichloroacetimidate; substituted or unsubstituted saturated or unsaturated phosphinoyl, such as diethylphosphinoyl; substituted or unsubstituted
25 aliphatic or aromatic sulphonyl group, such as tosylate. Preferred leaving groups are halogen atoms such as bromo, fluoro and chloro, more preferably, chloro.

The treatment of compounds of formula (2) with the sulfonation agent can be carried out under heating (approximately between 25° to 250° C, preferably between 70° and
30 100°) and agitation. After the sulfonation treatment, the solvent and any remaining sulfonation agent are removed from the slurry thus obtained. This removal can be accomplished by repeated washing with water, ultrafiltration, reverse osmosis, centrifugation, and/or filtration or the like.


35 The sulfonation procedures applicable for the preparation of sulfonated benzoxazoles can also be found in "Sulfonation and Related Reactions", by E. E. Gilbert, R. E. Krieger Publishing Co. Huntington, N.Y. (1977), "Mechanistic Aspects of Aromatic Sulfonation and Desulfonation", by H. Cerfontain, Interscience Publishers, NY (1968),

and in US6455738, "Process for the sulfonation of an aromatic compound", all incorporated herein by reference.

In particular, halosulfonyl benzoxazoles can be prepared by the reaction of a suitable Grignard or alkyl lithium reagent with sulfonyl chloride, or sulfur dioxide followed by oxidation with a halogen, preferably chlorine. Also, thiols may be oxidized to sulfonyl chlorides using chlorine in the presence of water under carefully controlled conditions. Additionally, sulfonic acids may be converted to sulfonyl halides using reagents such as PCl_5 , and also to anhydrides using suitable dehydrating reagents. The sulfonic acids may in turn be prepared using procedures well known in the art. Such sulfonic acids are also commercially available.

Alternatively, the 2-amino-chlorosulfonylbenzoxazole derivative of formula (3) may be prepared following the procedure described in EP0445926.

Similar methods may be employed for the sulfonation of benzoxazole derivatives in the 4, 5, 6, and 7 positions. However, substitution of the sulfonyl group on the C-6 position of the benzoxazole derivative of formula (2) is preferred, as shown in formula (3''') below.




Conveniently, the ratios of equivalents between the compound of formula (2) and the sulfonation agent range from 1:2 to 1:8, respectively. Preferably, the ratio of equivalents between the compound of formula (2) and the sulfonation agent is from 1:3 to 1:5, more preferably the ratio is around 1:4.3. The ratios of equivalents between the compound of formula (2) and the agent for coupling a suitable leaving group range from 1:1 to 1:5, respectively. Preferably, the ratio of equivalents between the compound of formula (2) and the agent for coupling a suitable leaving group is from 1:1.1 to 1:3, more preferably the ratio is around 1:1.2.

In an embodiment of the invention, the sulfonation reaction is carried out in the presence of about 4.27 equivalents of chlorosulfonic acid, 1.2 equivalents of thionyl chloride and ethyl acetate, by stirring the chlorosulfonic acid under nitrogen, adding compound of formula (2) at a temperature below 60° , stirring overnight at around


85°C, cooling down to a temperature below 65°C and adding around 1.2 equivalents of thionyl chloride and stirring overnight at a temperature around 65°C.

- 5 In an embodiment the halogenating agent is sulfonylchloride, resulting in the sulfonylchloride of formula (3'), wherein E is selected from the group as defined above.



- 10 A preferred embodiment is the chlorosulfonation of intermediate of formula (2) by reacting the intermediate at a temperature of 50 to 130 °C in an organic solvent of dichloromethane, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane, etc., or without organic solvent, in the presence of 2.5 to 5.0 equivalents of chlorosulfonic acid. Also, in the reaction, though it is variable depending on the E moiety, 2-substituted sulfonic acid is
15 obtained as a product along with 2-substituted sulfonylchloride (formula 3') in the form of mixture. Without an isolating step, the mixture is preferably treated with a chlorination reagent of SOCl₂, to obtain 2-substituted sulfonylchloride (formula 3') only. Alternatively, the mixture can be isolated by recrystallization to give a pure 2-substituted sulfonic acid which is then treated with a chlorination reagent of SOCl₂ to
20 be converted into 2-substituted sulfonylchloride (formula (3')).


In an embodiment the sulfonyl derivatives of formula (3) is a compound of formula (3'''), wherein E and LG are selected from the groups as defined above.



25

Compounds of formula (5)

- Compound of formula (5) may be obtained by amination of an epoxide-containing compound of formula (4) in the presence of a suitable solvent system. Compound of
30 formula (4) additionally encompasses a protecting group moiety (PG) for protecting the amino moiety.



Compound of formula (4) may be prepared in several ways available in the literature, for example as described in WO95/06030, which is incorporated herein by reference.

The term "amination" as used herein refers to a process in which an amino group or substituted amine is introduced into an organic molecule. Amination of epoxides is described for instance in March, *Advanced Organic Chemistry* 368-69 (3rd Ed. 1985) and McManus et al., *3 Synth. Comm.* 177 (1973), which are incorporated herein by reference. Suitably, compound of formula (5) may be prepared according to the procedure described in WO97/18205.

Amination agents which are used in the reaction include ammonia, ammonia generating compounds or organic amines. The ammonia generating compounds are inorganic compounds which generate ammonia gas on thermal decomposition thereof. Such inorganic compounds include ammonium carbonate, ammonium sulfate, etc. The organic amines include primary amine or secondary amines, such as methylamine, ethylamine, n-propylamine, butylamine, ethanolamine, dialkylamine such as dimethylamine, diethylamine, diisopropylamine, diethanolamine, methylethylamine, cyclohexylamine, aminopyridine, aniline, methylaniline, ethylaniline, n-propylaniline, isopropylaniline, dimethylaniline, diethylaniline, dipropylaniline, methylethylaniline; methylpropylaniline, etc. Tertiary amines may as well be employed for introducing strongly basic ion exchange groups, and are, for example, trialkylamines such as trimethylamine or triethylamine, or triethanolamine. Also diamines are useful such as alkylene diamines, preferably 1,3-diaminopropane, 1,4-diaminobutane or 1,6-diaminohexane. A preferred amination agent is a polyamine or oligoamine such as $\text{H}-(\text{NH}-\text{CH}_2-\text{CH}_2)_q-\text{NH}_2$, wherein q is a digit from 1 up to 10. Another preferred amination agent is isobutylamine.

Suitable solvent systems include protic, non-protic and dipolar aprotic organic solvents such as, for example, those wherein the solvent is an alcohol, such as methanol, ethanol, isopropanol, n-butanol, t-butanol, and the like, ethers such as tetrahydrofuran, dioxane and the like, toluene, N,N-dimethylformamide, dimethyl sulfoxide, and mixtures thereof. A preferred solvent is isopropanol.


Compounds of formula (4) additionally comprise an amino-protecting group. The term "amino-protecting group" as used herein refers to one or more selectively removable substituents on the amino group commonly employed to block or protect the amino functionality against undesirable side reactions during synthetic procedures and includes all conventional amino protecting groups. Examples of amino-protecting groups include the urethane blocking groups, such as t-butoxy-carbonyl ("Boc"), 2-(4-biphenyl)propyl(2)oxycarbonyl ("Bpoc"), 2-phenylpropyl(2)oxycarbonyl ("Poc"), 2-(4-xenyl)isopropoxycarbonyl, isopropoxycarbonyl, 1,1-diphenylethyl(1)-oxycarbonyl, 1,1-diphenylpropyl(1)oxycarbonyl, 2-(3,5-dimethoxyphenyl)propyl(2)-oxycarbonyl ("Ddz"), 2-(p-5-toluy)propyl(2)oxycarbonyl, 1-methylcyclopentanyloxy-carbonyl, cyclohexanyloxy-carbonyl, 1-methylcyclohexanyloxy-carbonyl, 2-methyl-cyclohexanyloxy-carbonyl, ethoxycarbonyl, 2-(4-toluy)sulfonyl)ethoxycarbonyl, 2-(methylsulfonyl)-ethoxycarbonyl, 2-(triphenylphosphino)-ethoxycarbonyl, 9-fluoroenylmethoxycarbonyl ("Fmoc"), 2-(trimethylsilyl)ethoxycarbonyl, allyloxy-carbonyl, 1-(trimethylsilylmethyl)prop-1-enyloxy-carbonyl, 5-benzisoxalyl-methoxycarbonyl, 4-acetoxybenzyloxy-carbonyl, 2,2,2-trichloroethoxycarbonyl, tribromoethoxycarbonyl, 2-ethynyl(2)propoxycarbonyl, cyclopropylmethoxycarbonyl, isobornyloxy-carbonyl, 1-piperidylloxy-carbonyl, benzyloxy-carbonyl ("Z" or "Cbz"), 4-phenylbenzyloxy-carbonyl, 2-methylbenzyloxy-carbonyl, α -2,4,5-tetramethyl-benzyloxy-carbonyl ("Tmz"), 4-methoxybenzyloxy-carbonyl, 4-fluorobenzyloxy-carbonyl, 4-chlorobenzyloxy-carbonyl, 3-chlorobenzyloxy-carbonyl, 2-chlorobenzyloxy-carbonyl, dichlorobenzyloxy-carbonyl, 4-bromobenzyloxy-carbonyl, ortho-bromobenzyloxy-carbonyl, 3-bromobenzyloxy-carbonyl, 4-nitrobenzyloxy-carbonyl, 4-cyanobenzyloxy-carbonyl, 4-(decyloxy)benzyloxy-carbonyl, and the like; the benzoylmethylsulfonyl group, dithiasuccinoyl ("Dts") group, the 2-(nitro)phenylsulfenyl group ("Nps"), the diphenylphosphine oxide group, and the like. The species of amino-protecting group employed is usually not critical so long as the derivatized amino group is stable to the conditions of the subsequent reactions and can be removed at the appropriate point without disrupting the remainder of the compound.

Additional examples of amino protecting groups include phenylacetyl, formyl ("For"), trityl (Trt), acetyl, trifluoroacetyl (TFA), trichloroacetyl, dichloroacetyl, chloroacetyl, bromoacetyl, iodoacetyl, benzoyl, tert-amylloxycarbonyl, tert-butoxycarbonyl, 3,4-dimethoxybenzyloxy-carbonyl, 4-(phenylazo)benzyloxy-carbonyl, 2-furfuryloxy-carbonyl, diphenylmethoxycarbonyl, 1,1-dimethylpropoxycarbonyl, phthalyl or phthalimido, succinyl, alanyl, leucyl, and 8-quinolyloxy-carbonyl, benzyl, diphenylmethyl, 2-nitrophenylthio, 2,4-dinitrophenylthio, methanesulfonyl, para-toluenesulfonyl, N,N-dimethylaminomethylene, benzylidene, 2-hydroxybenzylidene,

- 2-hydroxy-5-chlorobenzylidene, 2-hydroxy-1-naphthylmethylene, 3-hydroxy-4-pyridylmethylene, cyclohexylidene, 2-ethoxycarbonylcyclohexylidene, 2-ethoxycarbonylcyclopentylidene, 2-acetylcyclohexylidene, 3,3-dimethyl-5-oxocyclohexylidene, diphenylphosphoryl, dibenzylphosphoryl, 5-methyl-2-oxo-2H-1,3-dioxol-4-yl-methyl, trimethylsilyl, triethylsilyl, triphenylsilyl, 2-(p-biphenyl)-1-methylethoxycarbonyl, diisopropylmethoxycarbonyl, cyclopentylloxycarbonyl, adamantylloxycarbonyl, triphenylmethyl, trimethylsilane, phenylthiocarbonyl, para-nitrobenzylcarbonyl.
- 10 Other amino protecting groups include 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10-tetrahydrothio-xanthyl)]methyloxycarbonyl; 2-trimethylsilylethyloxycarbonyl; 2-phenylethyloxycarbonyl; 1,1-dimethyl-2,2-dibromoethyloxycarbonyl; 1-methyl-1-(4-biphenyl)ethyloxycarbonyl; p-nitrobenzyloxycarbonyl; 2-(p-toluenesulfonyl)-ethyloxycarbonyl; m-chloro-p-acyloxybenzyloxycarbonyl; 5-benzyisoxazolylmethyl-oxycarbonyl; p-(dihydroxyboryl)benzyloxycarbonyl; m-nitrophenyloxycarbonyl; o-nitrobenzyloxycarbonyl; 3,5-dimethoxybenzyloxycarbonyl; 3,4-dimethoxy-6-nitrobenzyloxycarbonyl; N'-p-toluenesulfonylaminocarbonyl; t-amylloxycarbonyl; p-decyloxybenzyloxycarbonyl; 2,2-dimethoxycarbonylvinyloxycarbonyl; di(2-pyridyl)methyloxycarbonyl; 2-furanylmethyloxycarbonyl; dithiasuccinimide;
- 20 2,5-dimethylpyrrole; 5-dibenzylsuberyl; and, methanesulfonamide. Preferred amino-protecting groups are Boc, Z / Cbz and Fmoc.

- Further examples of amino-protecting groups are well known in organic synthesis and the peptide art and are described by, for example T. W. Greene and P. G. M. Wuts,
- 25 *Protective Groups in Organic Synthesis*, 2nd ed., John Wiley and Sons, New York, Chapter 7, 1991; M. Bodanzsky, *Principles of Peptide Synthesis*, 1st and 2nd revised ed., Springer-Verlag, New York, 1984 and 1993; Stewart and Young, *Solid Phase Peptide Synthesis*, 2nd ed., Pierce Chemical Co, Rockford, IL 1984; L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons
- 30 (1994); L. Paquette, ed. *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995). Suitable amino protecting groups are also given in e.g. WO 98/07685.

- In an embodiment the intermediate having formula (5) can be prepared by reacting
- 35 intermediate compound of formula (4) with an amine of formula H_2N-R_4 , wherein R_4 is selected from the group as defined above. Exemplary amines corresponding to the formula H_2N-R_4 include benzylamine, isobutylamine, n-butylamine, pentylamine, isoamylamine, cyclohexanemethylamine, naphthylenemethylamine and the like.



In this above scheme, enantiomerically pure compounds of formula (5) can only
 5 obtained if compound of formula (4) is enantiomerically pure. If compounds of
 formula (4) are a mixture of stereoisomers, then compounds of formula (5) will also
 consist of a mixture of stereoisomers.


Conveniently the reaction can be conducted over a wide range of temperatures, e.g.,
 10 from about -20°C to about 200°C, but is preferably, but not necessarily, conducted at a
 temperature at which the solvent begins to reflux.

Suitably the ratios of equivalents between the compound of formula (4) and the
 amination agent may range from 1:1 to 1:99, respectively. Preferably, the ratio of
 15 equivalents between the compound of formula (4) and the amination agent is from 1:10
 to 1:20, more preferably the ratio is around 1:14.


In an embodiment of the invention, the amination reaction is carried out in the presence
 of about 14 equivalents of isobutylamine, at ambient temperature, and stirring
 20 overnight at a temperature around 65°C.

Compounds of formula (6)


Compound of formula (6) is obtained by coupling the intermediate of formula (3) with
 compound of formula (5), wherein the protecting group (PG), the substituents R₂, R₃,
 25 R₄, the leaving group (LG), and the electrophilic moiety (E) are as described above.



An alternative route to the preparation of formula (6) would consist of an amination of compound of formula (3) obtaining compound of formula (11)



followed by attack by the amino function of compound of formula (11) onto the epoxide carbon atom of compound of formula (4) to yield compound of formula (6).




A particular group of compounds are those compounds of formula (6) wherein one or more of the following restrictions apply:

- 20
- R_2 is hydrogen;
 - R_3 is aryl/ C_{1-4} alkyl, in particular, arylmethyl, more in particular phenylmethyl;
 - R_4 is unsubstituted C_{1-6} alkyl or C_{1-6} alkyl substituted with one or more substituents selected from aryl, Het^1 , Het^2 , C_{3-7} cycloalkyl and amino optionally mono- or disubstituted where the substituents are selected from C_{1-4} alkyl, aryl, Het^1 and Het^2 .

25

A preferred group of compounds of formula (6) are those compounds where the sulfonamide group is attached to the benzoxazole group in the 6-position, as indicated in formula (6'') below.




An interesting group of compounds are those of formula (6) wherein R_2 is selected from the groups as defined above, wherein R_3 is selected from the group comprising C_{1-4} alkyl, aryl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, aryl C_{1-4} alkyl, and wherein R_4 is hydrogen or C_{1-4} alkyl.



A suitable group of compounds are those compounds of formula (6), wherein R_2 is hydrogen; R_3 is aryl C_{1-4} alkyl; and R_4 is C_{1-4} alkyl; in particular, R_2 is hydrogen; R_3 is arylmethyl; and R_4 is isobutyl.

A suitable group of compounds are those compounds of formula (6) as a salt, wherein the salt is selected from trifluoroacetate, fumarate, chloroacetate and methanesulfonate.

A particularly interesting compound according to the invention is the compound with formula (6''').



In a more preferred embodiment, the sulfonyl derivative of formula (3) is a sulfonylhalide of formula (3''), wherein X is fluoro, chloro, bromo, iodo, preferably chloro; said sulfonylhalide is reacted with an intermediate of formula (5'), wherein R_2 is hydrogen, R_3 is benzyl, and R_4 is isobutyl, to yield a compound according to the invention having preferred formula (6'''), wherein PG is preferably Boc, and E is methyl.




5

- The present compounds according to the invention having general formula (6) are prepared by reacting a sulfonyl derivative of formula (3) with a suitable intermediate of formula (5) in suitable solvents under alkaline conditions. Suitable alkaline conditions include bases as the ones mentioned above and acid scavengers, such as triethylamine and pyridine. Suitable solvents have also been illustrated above, being inert solvents preferred, such as for example ethylacetate, methylene chloride, dichloromethane, and tetrahydrofuran.
- 15 The ratios of equivalents between the compound of formula (4) and compound of formula (3) may range from 1:1 to 1:8, respectively. Preferably, the ratio of equivalents between the compound of formula (4) and the compound of formula (3) is from 1:1.1 to 1:4, more preferably the ratio is around 1:1.2.
- 20 In an embodiment of the invention, the production of compound of formula (6) is carried out by stirring a solution of compound of formula (5) at a temperature above 65°C, adding the base, cooling down to 50°C and adding compound of formula (3) during 3 hours maintaining the reaction temperature between 40° and 50°C. In another embodiment, the synthesis of compound of formula (6) is performed at lower
- 25 temperatures, for example from -20° to 150°C, preferably around room temperature.

Intermediates of formula (6) are also active inhibitors of retrovirus proteases.

Compounds of formula (7)

Compound of formula (7) is obtained by amination of compound of formula (6) in the presence of an amination agent, and a solvent.



Suitable amination agents are as mentioned above, being methylamine preferred.

Suitable solvents are as mentioned above, being isopropanol, and acetonitrile preferred.

10

The moieties $-R_6$ and $-R_8$ may be directly introduced by the amination agents, or subsequently introduced by a second reaction on the amino group.

15 The ratios of equivalents between the compound of formula (6) and the amination agent may range from 1:1.1 to 1:99, respectively. Preferably, the ratio of equivalents between the compound of formula (6) and the amination agent is around 1:35.

20 In an embodiment, compound of formula (7) is prepared by suspending compound of formula (6) in a solvent till complete dissolution. The amination agent is then added and the resulting solution is stirred and heated for 1 hour at a temperature between 20° and 180°C, preferably around 65°C.

Compounds of formula (8)

25 Removal of the amino protecting group to obtain compound of formula (8) can be achieved using conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like, thus using commonly known acids in suitable solvents.

30 Examples of acids employed in the removal of the amino protecting group include inorganic acids such as hydrogen chloride, nitric acid, hydrochloric acid, sulfuric acid and phosphoric acid; organic acids such as acetic acid, trifluoroacetic acid methanesulfonic acid and p-toluenesulfonic acid; Lewis acids such as boron trifluoride; acidic cationic ion-exchange resins such as Dowex 50W™. Of these acids, inorganic acids and organic acids are preferred. Hydrochloric acid, sulfuric acid, phosphoric acid and trifluoroacetic acid are more preferred, and hydrochloric acid is most preferred. 35 Preferably, the acids employed are either 20% trifluoroacetic acid or hydrochloric acid, and the like, in methylene chloride or 4M HCl in dioxane.

The solvent employed is not particularly limited provided that it has no adverse effect on the reaction and dissolves the starting materials to at least some extent. Suitable solvents are aliphatic hydrocarbons such as hexane, heptane and petroleum ether; aromatic hydrocarbons such as benzene, toluene, xylene and mesitylene; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, propanol, isopropanol and butanol; esters such as methyl acetate, ethyl acetate, methyl propionate and ethyl propionate; nitrites such as acetonitrile; amides such as N,N-dimethylformamide and N,N-dimethylacetamide; sulfoxides such as dimethyl sulfoxide and mixtures thereof. Aromatic hydrocarbons, alcohols and esters are preferred. Alcohols and esters are more preferred, and isopropanol, ethanol and ethyl acetate are particularly preferred. Alternatively, mixtures of ethanol and dioxane are also preferred.

The reaction temperature employed depends upon various factors such as the nature of the starting materials, solvents and acids. However it is usually between -20° C and 150° C, and is preferably between 10° C and 100° C. The reaction time employed depends on the reaction temperature and the like. It is typically from 5 minutes to 24 hours, and preferably from 10 minutes to 10 hours.

Examples of reagents and methods for deprotecting amines from amino protecting groups can additionally be found in *Protective Groups in Organic Synthesis* by Theodora W. Greene, New York, John Wiley and Sons, Inc., 1981, incorporated herein by reference.

As those skilled in the art will recognize, the choice of amino protecting group employed in a previous step of the process will dictate the reagents and procedures used in removing said amino protecting group.

The ratios of equivalents between the compound of formula (7) and the acid in solvent may range from 1:2 to 1:50, respectively. Preferably, the ratio of equivalents between the compound of formula (7) and the acid is from 1:2 to 1:8, more preferably the ratio is around 1:4.

In an embodiment of the invention, the removal of the amino protecting group of compound of formula (7) to generate compound of formula (8) is carried out by stirring a solution of compound of formula (7) in a suitable solvent at a temperature around 65°C, and adding the acid in solvent during 30 minutes. Preferably, prior to the stirring


of a solution of compound of formula (7), an azeotropic distillation is applied in order to remove the content of water.

A preferred method involves removal of the protecting group, e.g., removal of a carbobenzoxy group, by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. Where the protecting group is a t-butoxycarbonyl group, it can be removed utilizing an inorganic or organic acid, e.g., HCl or trifluoroacetic acid, in a suitable solvent system, e.g., dioxane or methylene chloride. The resulting product is the amine salt derivative. Generally, the reaction is carried out at a temperature ranging from about 0° C to about 60° C. Generally, the reaction requires from about 1 to 24 hours. The deprotected amine of formula (8) may be isolated and purified by techniques well known in the art, such as extraction, evaporation, chromatography and recrystallization.

An alternative way of preparing compounds of formula (7), (8), and (9), wherein both R₆ and R₈ are hydrogen, can be performed by replacing one of R₆ or R₈ by a suitable amino-protecting group. In such a case, deprotection may occur simultaneously with the deprotection of the nitrogen atom on the left-hand side of the molecule.

Compounds of formula (9)

Compound of formula (8) may be reacted with a suitable reagent to couple a radical of formula R₁-L-, thus obtaining the corresponding 2-amino-benzoxazole sulfonamide protease inhibitors.




(9)

The coupling of a radical of formula R₁-L- may be performed in the presence of a base such as triethylamine (for alcohols to generate a carbamate) and optionally in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid (EDC) and 1-hydroxybenzotriazole (HOBT) (for carboxylic acids to generate an amide) or an alcohol such as *tert*-butanol, and in a suitable solvent such as dichloromethane. Reagents suitable to introduce radical of formula R₁-L- are reagents like R₁-L-LG, wherein LG is a leaving group, as described throughout the specification. Particularly, reagents of formula R₁-L-C(=O)-OH are suitable to couple radicals of formula R₁-L- into compounds of formula (8).

Compounds of formula (8) and (9) may as well be prepared as described in WO95/06030, and US-5,968,942, which are incorporated herein by reference.

- 5 An interesting group of compounds are those of formula (9) wherein R_1 is a radical of formula (10)



(10)

10

- R_9 , R_{10a} and R_{10b} are, each independently, hydrogen, C_{1-4} alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyl, C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{1-4} alkyl optionally substituted with aryl, Het^1 , Het^2 , C_{3-7} cycloalkyl, C_{1-4} alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyl, aminosulfonyl, C_{1-4} alkylS(O)_t, hydroxy, cyano, halogen or amino optionally mono- or disubstituted where the substituents are selected from C_{1-4} alkyl, aryl, aryl C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, Het^1 , Het^2 , Het^1C_{1-4} alkyl and Het^2C_{1-4} alkyl; whereby R_9 , R_{10a} and the carbon atoms to which they are attached may also form a C_{3-7} cycloalkyl radical;

- 15 R_{11b} is hydrogen, C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, Het^1 , Het^2 or C_{1-4} alkyl optionally substituted with halogen, hydroxy, C_{1-4} alkylS(=O)_t, aryl, C_{3-7} cycloalkyl, Het^1 , Het^2 , amino optionally mono- or disubstituted where the substituents are selected from C_{1-4} alkyl, aryl, aryl C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, Het^1 , Het^2 , Het^1C_{1-4} alkyl and Het^2C_{1-4} alkyl; whereby R_{11b} may be linked to the remainder of the molecule via a sulfonyl group;

t is zero, one or two;

L is $-C(=O)-$, $-O-C(=O)-$, $-NR_{12}-C(=O)-$, $-O-C_{1-6}$ alkanediyl- $C(=O)-$, $-NR_{12}-C_{1-6}$ alkanediyl- $C(=O)-$, $-S(=O)_2-$, $-O-S(=O)_2-$, $-NR_{12}-S(=O)_2$ whereby either the $C(=O)$ group or the $S(=O)_2$ group is attached to the NR_2 moiety;

- 30 R_{12} is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, aryl C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl- C_{1-6} alkyl, aryl, Het^1 , Het^1C_{1-6} alkyl, Het^2 , Het^2C_{1-6} alkyl; and

R_4 is hydrogen, C_{1-4} alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyl, C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{1-6} alkyl optionally substituted with one or more substituents selected from aryl, Het^1 , Het^2 ,

- 35 C_{3-7} cycloalkyl, C_{1-4} alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or

di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, C₁₋₄alkylS(=O)₂, hydroxy, cyano, halogen and amino optionally mono- or disubstituted where the substituents are selected from C₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, Het¹, Het², Het¹C₁₋₄alkyl and Het²C₁₋₄alkyl.

5

A particular group of compounds are those compounds of formula (9) wherein one or more of the following restrictions apply:

R₁ is hydrogen, Het¹, Het², aryl, Het¹C₁₋₆alkyl, Het²C₁₋₆alkyl, arylC₁₋₆alkyl, more in particular, R₁ is a saturated or partially unsaturated monocyclic or bicyclic heterocycle having 5 to 8 ring members, which contains one or more heteroatom ring members selected from nitrogen, oxygen or sulfur and which is optionally substituted, or phenyl optionally substituted with one or more substituents;

10

R₂ is hydrogen;

L is -C(=O)-, -O-C(=O)-, -O-C₁₋₆alkanediyl-C(=O)-, more in particular, L is -O-C(=O)- or -O-C₁₋₆alkanediyl-C(=O)-, whereby in each case the C(=O) group is attached to the NR₂ moiety;

15

R₃ is arylC₁₋₄alkyl, in particular; arylmethyl, more in particular phenylmethyl;

R₄ is optionally substituted C₁₋₆alkyl, in particular unsubstituted C₁₋₆alkyl or C₁₋₆alkyl optionally substituted with one or more substituents selected from aryl, Het¹, Het², C₃₋₇cycloalkyl and amino optionally mono- or disubstituted where the substituents are selected from C₁₋₄alkyl, aryl, Het¹ and Het²;

20

R₆ is hydrogen or methyl; and

R₈ is hydrogen or methyl.

25

A special group of compounds are those compounds of formula (9) wherein R₁-L is Het¹-O-C(=O), Het²-C₁₋₆alkanediyl-O-C(=O), aryl-O-C₁₋₆alkanediyl-C(=O) or aryl-C(=O).

Also a special group of compounds are those compounds of formula (9) wherein

30

NR₆R₈ is amino, monomethylamino or dimethylamino.

Of particular interest are those compounds of formula (9) wherein R₁ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, arylC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, aryl, Het¹, Het¹C₁₋₆alkyl, Het², Het²C₁₋₆alkyl, in particular, R₁ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, arylC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, aryl, Het², Het²C₁₋₆alkyl.


35

An interesting group of compounds are those compounds of formula (9) wherein R₁ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, arylC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, aryl, Het¹, Het¹C₁₋₆alkyl, Het², Het²C₁₋₆alkyl; wherein Het¹ is a saturated or partially

unsaturated monocyclic heterocycle having 5 or 6 ring members, which contains one or more heteroatom ring members selected from nitrogen, oxygen or sulfur and which is optionally substituted on one or more carbon atoms.

- 5 Another interesting group of compounds are those compounds of formula (9) wherein L is $-O-C_{1-6}\text{alkanediyl}-C(=O)-$.

A preferred group of compounds are those compounds where the sulfonamide group is attached to the benzoxazole group in the 6-position, as indicated in formula (9''') below.



- A suitable group of compounds are those compounds of formula (9) wherein R_1 is aryl or aryl C_{1-6} alkyl; in particular the aryl moiety of the R_1 definition is further substituted on one or more ring members, whereby each substituent is independently selected from C_{1-4} alkyl, hydroxy, halogen, optionally mono- or disubstituted amino, optionally mono- or disubstituted amino C_{1-4} alkyl, nitro and cyano; preferably the substituent is selected from methyl, ethyl, chlorine, iodine, bromine, hydroxy and cyano, in particular the aryl moiety contains 6 to 12 ring members, more in particular the aryl moiety in the definition of R_1 contains 6 ring members.

- A suitable group of compounds are those compounds of formula (9) wherein R_1 is Het^2 or $\text{Het}^2C_{1-6}\text{alkyl}$, wherein the Het^2 in the definition of R_1 contains one or more heteroatoms each independently selected from nitrogen, oxygen and sulfur; in particular the Het^2 moiety of the R_1 definition is further substituted on one or more ring members, whereby each substituent is independently selected from C_{1-4} alkyl, hydroxy, halogen, optionally mono- or disubstituted amino and cyano; preferably the substituent is selected from methyl, ethyl, chlorine, iodine, bromine, hydroxy, amino and cyano.

- Another group of compounds are those of formula (9) wherein R_1 is Het^2 or $\text{Het}^2C_{1-6}\text{alkyl}$, L is $-C(=O)-$, $-O-C(=O)-$, $-O-C_{1-6}\text{alkanediyl}-C(=O)-$; in particular the Het^2 moiety in the definition of R_1 is an aromatic heterocycle having 5 or 6 ring members, which contain one or more heteroatom ring members each independently selected from nitrogen, oxygen or sulfur, more in particular the Het^2 moiety is an

aromatic heterocycle having 5 or 6 ring members, which contain two or more heteroatom ring members each independently selected from nitrogen, oxygen or sulfur.

A suitable group of compounds are those compounds of formula (9) wherein R_1 is
5 $Het^1C_{1-6}alkyl$, Het^1 , wherein said Het^1 in the definition of R_1 is monocyclic having 5 or 6 ring members, wherein the Het^1 contains one or more heteroatoms each independently selected from nitrogen, oxygen and sulfur; in particular the Het^1 moiety of the R_1 definition is further substituted on one or more carbon atoms, whereby each
10 substituent is independently selected from $C_{1-4}alkyl$, hydroxy, halogen, optionally mono- or disubstituted amino and cyano; preferably the substituent is selected from methyl, ethyl, chlorine, iodine, bromine, hydroxy, amino and cyano.

A suitable group of compounds are those compounds of formula (9) wherein R_1 is Het^1 ,
15 wherein said Het^1 is bicyclic having 8 to 10 ring members, wherein the Het^1 contains one or more heteroatoms each independently selected from nitrogen, oxygen and sulfur; in particular the Het^1 moiety of the R_1 definition is further substituted on one or more carbon atoms, whereby each substituent is independently selected from $C_{1-4}alkyl$, hydroxy, halogen, optionally mono- or disubstituted amino and cyano; preferably the
20 substituent is selected from methyl, ethyl, chlorine, iodine, bromine, hydroxy, amino and cyano; in particular the Het^1 moiety contains 2 or more heteroatoms selected from nitrogen, sulfur and oxygen.

A suitable group of compounds are those compounds of formula (9) wherein R_1 is Het^1 ,
25 wherein said Het^1 is a saturated bicyclic group having 5 to 10 ring members, wherein the Het^1 contains one or more heteroatoms each independently selected from nitrogen, oxygen and sulfur; in particular the Het^1 moiety of the R_1 definition is further substituted on one or more carbon atoms, whereby each substituent is independently selected from $C_{1-4}alkyl$, hydroxy, halogen, optionally mono- or disubstituted amino and cyano; preferably the substituent is selected from methyl, ethyl, chlorine, iodine,
30 bromine, hydroxy, amino and cyano; in particular Het^1 contains 5 to 8 ring members; in particular the Het^1 moiety has 6 to 8 ring members wherein Het^1 contains 2 or more heteroatoms selected from nitrogen, sulfur and oxygen.

An interesting group of compounds are those compounds of formula (9) wherein R_1 is
35 Het^1 , Het^2 , $Het^1-C_{1-6}alkyl$, or $Het^2-C_{1-6}alkyl$, wherein Het^1 and Het^2 are selected from thiazolyl, imidazolyl, oxazolyl, oxadiazolyl, dioxazolyl, pyrazolyl, pyrazinyl, imidazolinonyl, quinolinyl, isoquinolinyl, indolyl, pyridazinyl, pyridinyl, pyrrolyl, pyranyl, pyrimidinyl, furanyl, triazolyl, tetrazolyl, benzofuranyl, benzoxazolyl, isoxazolyl, isothiazolyl, thiadiazolyl, thiophenyl, tetrahydrofurofuranyl,

tetrahydropyranofuranyl, benzothiophenyl, carbazoyl, imidazolonyl, oxazolonyl, indoliziny, triaziny, quinoxaliny, piperidiny, piperaziny, morpholiny, thiamorpholiny, pyraziny, thienyl, tetrahydroquinoliny, tetrahydroisoquinoliny, β -carboliny, dioxany, dithianyl, oxolany, dioxolany, tetrahydrothiophenyl, 5 tetrahydropyrany, tetrahydropyrany; wherein Het¹ and Het² are optionally benzofused; wherein Het¹ and Het² are optionally further substituted on one or more ring members; preferably Het² is selected from thiazolyl, imidazolyl, oxazolyl, oxadiazolyl, pyrazolyl, pyridiny, optionally substituted on one or more ring members.

10 A suitable group of compounds are those compounds of formula (9), wherein R₂ is hydrogen; R₃ is alkylaryl; and R₄ is C₁₋₄alkyl; in particular, R₂ is hydrogen; R₃ is methylaryl; and R₄ is isobutyl.

A suitable group of compounds are those compounds of formula (9) as a salt, wherein 15 the salt is selected from trifluoroacetate, fumarate, chloroacetate and methanesulfonate.

A convenient way of preparing compounds of formula (9) wherein both R₆ and R₈ are hydrogen can be prepared analogously to the procedure described in scheme A, and whereby one of R₆ or R₈ is replaced by a suitable protecting group (PG) such as, for 20 example, an acetyl or an alkyloxycarbonyl group, or any other as mentioned above. In such a case, deprotection may occur simultaneously with the deprotection of the nitrogen atom on the left-hand side of the molecule.

In a particular embodiment, the method for preparing a retrovirus protease inhibitor of 25 the present invention, and in particular a 2-amino-benzoxazole sulfonamide protease inhibitor comprises the steps of

- reacting a compound of general formula (6) wherein PG, R₂, R₃, R₄ and E are independently selected from the group as defined above, with ammonium to yield an intermediate of formula (7),
- 30 • deprotecting the obtained intermediate of formula (7) and
- reacting the deprotected intermediate of formula (8) in a suitable solvent with a suitable radical of formula R₁-L- for yielding a retrovirus protease inhibitor.

Example 2, provided below, illustrates the preparation of a 2-amino-benzoxazole sulfonamide protease inhibitor according to this method.

35

In another particular embodiment, the method for preparing a retrovirus protease inhibitor, and in particular a 2-amino-benzoxazole sulfonamide protease inhibitor comprises the steps of

- reacting a compound of general formula (6) wherein PG, R₂, R₃, R₄ and E are independently selected from the group as defined above, with methyl amine to yield an intermediate of formula (7),
- deprotecting the obtained intermediate of formula (7), and
- 5 • reacting the deprotected intermediate of formula (8) in a suitable solvent with a suitable radical of formula R₁-L- for yielding a retrovirus protease inhibitor.

Example 3, provided below, illustrates the preparation of a 2-amino-benzoxazole sulfonamide protease inhibitor according to this method.

- 10 The compounds of formula (6), (7), (8) and (9) may also be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form. Said N-oxidation reaction may generally be carried out by reacting the starting material of formulas (6), (7), (8) and (9) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example,
- 15 hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chloro-benzenecarboperoxoic acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. ter-butyl hydroperoxide.
- 20 Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

- 25 In preparations presented above, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, distillation, trituration and chromatography.

- 30 Whenever the term "substituted" is used in the present invention, it is meant to indicate that one or more hydrogens on the atom indicated in the expression using "substituted" is replaced with a selection from the indicated group, provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.

- 35 As used herein, the term "halo" or "halogen" as a group or part of a group is generic for fluoro, chloro, bromo or iodo.

The term "alkyl", alone or in combination, means straight and branched chained saturated hydrocarbon radicals containing from 1 to 10 carbon atoms, preferably from 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, 2-methylbutyl, pentyl, iso-amyl, hexyl, 3-methylpentyl, octyl and the like.

The term "C₁₋₄alkyl" as a group or part of a group defines straight and branched chained saturated hydrocarbon radicals having from 1 to 4 carbon atoms, such as, for example, methyl, ethyl, propyl, butyl and 2-methyl-propyl.

The term "C₁₋₆alkyl" as a group or part of a group defines straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for C₁₋₄alkyl and pentyl, hexyl, 2-methylbutyl, 3-methylpentyl and the like.

The term "C₂₋₆alkenyl" as a group or part of a group defines straight and branched chained hydrocarbon radicals having from 2 to 6 carbon atoms containing at least one double bond such as, for example, ethenyl, propenyl, butenyl, pentenyl, hexenyl and the like.

The term "C₂₋₆alkynyl" as a group or part of a group defines straight and branched chained hydrocarbon radicals having from 2 to 6 carbon atoms containing at least one triple bond such as, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like.

The term "C₁₋₆alkanediyl" as a group or part of a group defines bivalent straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methylene, ethan-1,2-diyl, propan-1,3-diyl, propan-1,2-diyl, butan-1,4-diyl, pentan-1,5-diyl, hexan-1,6-diyl, 2-methylbutan-1,4-diyl, 3-methyl-pentan-1,5-diyl and the like.

The term "cycloalkyl" alone or in combination, means a saturated or partially saturated monocyclic, bicyclic or polycyclic alkyl radical wherein each cyclic moiety contains from about 3 to about 8 carbon atoms, more preferably from about 3 to about 7 carbon atoms. Examples of monocyclic cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. Examples of polycyclic cycloalkyl radicals include decahydronaphthyl, bicyclo [5.4.0] undecyl, adamantyl, and the like.

The term "C₃₋₇cycloalkyl" as a group or part of a group is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

- The term "aryl" as a group or part of a group is meant to include phenyl and naphthyl which both may be optionally substituted with one or more substituents independently selected from C₁₋₆alkyl, optionally mono- or disubstituted aminoC₁₋₆alkyl, C₁₋₆alkyloxy, halogen, hydroxy, hydroxyC₁₋₆alkyl, optionally mono- or disubstituted amino, nitro, cyano, haloC₁₋₆alkyl, carboxyl, C₁₋₆alkoxycarbonyl, C₃₋₇cycloalkyl, Het¹, optionally mono- or disubstituted aminocarbonyl, methylthio, methylsulfonyl, and phenyl optionally substituted with one or more substituents, each independently selected from C₁₋₆alkyl, optionally mono- or disubstituted aminoC₁₋₆alkyl, C₁₋₆alkyloxy, halogen, hydroxy, optionally mono- or disubstituted amino, nitro, cyano, haloC₁₋₆alkyl, carboxyl, C₁₋₆alkoxycarbonyl, C₃₋₇cycloalkyl, Het¹, optionally mono- or disubstituted aminocarbonyl, methylthio and methylsulfonyl; whereby the optional substituents on any amino function are independently selected from C₁₋₆alkyl, C₁₋₆alkyloxy-D-, Het¹-D-, Het¹C₁₋₆alkyl, Het¹C₁₋₆alkyl-D-, Het¹oxy-D-, Het¹oxy-C₁₋₆alkyl-D-, phenyl-D-, phenyl-oxy-D-, phenyloxyC₁₋₆alkyl-D-, phenylC₁₋₆alkyl-D-, C₁₋₆alkyloxycarbonyl-amino-D-, amino-D-, aminoC₁₋₆alkyl and aminoC₁₋₆alkyl-D- whereby each of the amino groups may optionally be mono- or where possible di-substituted with C₁₋₆alkyl and whereby D is defined as C₁₋₆alkanediyl, -C(=O)-, -C(=S)-, -S(=O)₂-, C₁₋₆alkanediyl-C(=O)-, C₁₋₆alkanediyl-C(=S)- or C₁₋₆alkanediyl-S(=O)₂- whereby the point of attachment of D to the remainder of the molecule is the C₁₋₆alkanediyl group in those moieties containing said group.
- 25 The term "haloC₁₋₆alkyl" as a group or part of a group is defined as C₁₋₆alkyl substituted with one or more halogen atoms, preferably, chloro or fluoro atoms, more preferably fluoro atoms. Preferred haloC₁₋₆alkyl groups include for instance trifluoromethyl and difluoromethyl.
- 30 The term "hydroxyC₁₋₆alkyl" as a group or part of a group is defined as C₁₋₆alkyl substituted with one or more hydroxy groups.

- The term "Het¹" as a group or part of a group is defined as a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle having 3 to 14 ring members, preferably 5 to 10 ring members and more preferably 5 to 8 ring members, which contains one or more heteroatom ring members, each independently selected from nitrogen, oxygen or sulfur, and which is optionally substituted on one or more nitrogen ring atoms by C₁₋₆alkyl, and optionally substituted on one or more carbon atoms by

C₁₋₆alkyl, optionally mono- or disubstituted aminoC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxy, halogen, hydroxy, oxo, optionally mono- or disubstituted amino, nitro, cyano, haloC₁₋₆alkyl, carboxyl, C₁₋₆alkoxycarbonyl, C₃₋₇cycloalkyl, optionally mono- or disubstituted aminocarbonyl, methylthio, methylsulfonyl, optionally substituted phenyl; 5
whereby the optional substituents on any amino function are independently selected from C₁₋₆alkyl, C₁₋₆alkyloxy-D-, Het²-D-, Het²C₁₋₆alkyl, Het²C₁₋₆alkyl-D-, Het²oxy-D-, Het²oxyC₁₋₄alkyl-D-, aryl-D-, aryloxy-D-, aryloxyC₁₋₄alkyl-D-, arylC₁₋₆alkyl-D-, C₁₋₆alkyloxycarbonylamino-D-, amino-D-, aminoC₁₋₆alkyl and aminoC₁₋₆alkyl-D- 10
whereby each of the amino groups may optionally be mono- or where possible di-substituted with C₁₋₄alkyl and whereby D is as defined above.

The term "Het²" as a group or part of a group is defined as an aromatic monocyclic, bicyclic or tricyclic heterocycle having 5 to 14 ring members, preferably 5 to 10 ring members and more preferably 5 to 6 ring members, which contains one or more 15
heteroatom ring members each independently selected from nitrogen, oxygen or sulfur, and which is optionally substituted on one or more nitrogen ring atoms by C₁₋₆alkyl, and optionally substituted on one or more carbon atoms by C₁₋₆alkyl, optionally mono- or disubstituted aminoC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxy, halogen, hydroxy, optionally mono- or disubstituted amino, nitro, cyano, haloC₁₋₆alkyl, carboxyl, 20
C₁₋₆alkoxycarbonyl, C₃₋₇cycloalkyl, optionally mono- or disubstituted aminocarbonyl, methylthio, methylsulfonyl, phenyl; whereby the optional substituents on any amino function are independently selected from C₁₋₆alkyl, C₁₋₆alkyloxy-D-, Het¹-D-, Het¹C₁₋₆alkyl, Het¹C₁₋₆alkyl-D-, Het¹oxy-D-, Het¹oxyC₁₋₄alkyl-D-, aryl-D-, aryloxy-D-, aryloxyC₁₋₄alkyl-D-, arylC₁₋₆alkyl-D-, C₁₋₆alkyloxycarbonylamino-D-, amino-D-, 25
aminoC₁₋₆alkyl and aminoC₁₋₆alkyl-D- whereby each of the amino groups may optionally be mono- or where possible di-substituted with C₁₋₄alkyl and whereby D is as defined above.

The term "alkoxy" or "alkyloxy", alone or in combination, means an alkyl ether radical 30
wherein the term alkyl is as defined above. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, hexanoxy and the like.

The term "alkylthio" means an alkyl thioether radical, wherein the term "alkyl" is 35
defined as above. Examples of alkylthio radicals include methylthio (SCH₃), ethylthio (SCH₂CH₃), n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, n-hexylthio, and the like.

As used herein the term (=O) forms a carbonyl moiety with the carbon atom to which it is attached. The term (=O) forms a sulfoxide with the sulfur atom to which it is attached. The term (=O)₂ forms a sulfonyl with the sulfur atom to which it is attached.

- 5 As used herein the term (=S) forms a thiocarbonyl moiety with the carbon atom to which it is attached.

As used herein before, the term "one or more" covers the possibility of all the available atoms, where appropriate, to be substituted, preferably, one, two or three.

10

When any variable (e.g. halogen or C₁₋₄alkyl) occurs more than one time in any constituent, each definition is independent.

- 15 Whenever used in the present invention the term "compounds of the invention" or "benzoxazole sulfonamide compounds" or a similar term is meant to include the compounds of general formulas (3), (6), (7), (8), and (9) and any subgroup thereof. This term also refers to their *N*-oxides, salts, stereoisomeric forms, racemic mixtures, pro-drugs, esters and metabolites, as well as their quaternized nitrogen analogues. The *N*-oxide forms of said compounds are meant to comprise compounds wherein one or
- 20 several nitrogen atoms are oxidized to the so-called *N*-oxide.

- For therapeutic use, the salts of the compounds according to the invention, are those wherein the counter-ion is pharmaceutically or physiologically acceptable. However, salts having a pharmaceutically unacceptable counterion may also find use, for
- 25 example, in the preparation or purification of a pharmaceutically acceptable compound of the present invention. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.

- The pharmaceutically acceptable salts of the compounds according to the invention, i.e.
- 30 in the form of water-, oil-soluble, or dispersible products, include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate,
- 35 ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include

ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as sarginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be
5 quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl-bromides and others. Other pharmaceutically acceptable salts include the sulfate salt ethanolate
10 and sulfate salts.

The compounds according to the invention may also exist in their tautomeric forms. Such forms, although not explicitly indicated in the compounds described herein, are intended to be included within the scope of the present invention.
15

The term stereochemically isomeric forms of compounds of the present invention, as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of the present invention may possess.
20

Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically
25 isomeric forms of the compounds of the present invention both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.



Pure stereoisomeric forms of the compounds and intermediates as mentioned herein are
30 defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates. In particular, the term "stereoisomerically pure" concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i. e. minimum 90% of one isomer and maximum 10% of the other possible isomers) up to a stereoisomeric excess of 100% (i. e. 100%
35 of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to 100% and most in particular having a stereoisomeric excess of 97% up to 100%. The terms "enantiomerically pure" and "diastereomerically pure" should be understood in a similar way, but then having

regard to the enantiomeric excess, respectively the diastereomeric excess of the mixture in question.

Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures. For instance, enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphorsulfonic acid. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The diastereomeric racemates of the compounds and intermediates of this invention can be obtained separately by conventional methods. Appropriate physical separation methods which may advantageously be employed are, for example, selective crystallization and chromatography, e. g. column chromatography.

It is clear to a person skilled in the art that the compounds and intermediates of this invention contain at least two asymmetric centers and thus may exist as different stereoisomeric forms. These asymmetric centers are indicated with an asterisk (*) in the figures below.



The absolute configuration of each asymmetric center that may be present in the compounds and intermediates of this invention may be indicated by the stereochemical descriptors R and S, this R and S notation corresponding to the rules described in Pure Appl. Chem. 1976, 45,11-30.

The present invention is also intended to include all isotopes of atoms occurring on the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.

The reagents and solvents used throughout the specification may be replaced by functional alternatives or functional derivatives thereof as they are known to a person skilled in the art. Also the reaction conditions such as stirring times, purification and temperature may be adjusted to optimise reaction conditions. Similarly, the reaction products may be isolated from the medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, trituration and chromatography. A number of intermediates and starting materials used in the foregoing preparations are known compounds, while others may be prepared according to methods known in the art of preparing said or similar compounds.

The chemical reactions described are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials. Similarly, the order of the above mentioned steps in said processes may be different from the order cited above.

The compounds of formula (6) find their particular use in the preparation of a medicament. According to a preferred embodiment, the present compounds of formula (6) are used as precursor in the preparation of anti-viral drugs, in particular anti-HIV drugs, more in particular HIV protease inhibitors.

- The compounds of formula (6) and all intermediates leading to the formation of stereoisomerically pure compounds are of particular interest in preparing 2-amino-benzoxazole sulfonamide compounds, as HIV protease inhibitors, as disclosed in
- 5 WO 95/06030, WO 96/22287, WO 96/28418, WO 96/28463, WO 96/28464, WO 96/28465 WO 97/18205, and WO 02/092595 all incorporated herein by reference, and in particular, the following HIV-protease inhibitors of formula (9):
- (3-[(2-Amino-benzoxazole-6-sulfonyl)-pyridin-2-ylmethyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid tetrahydro-furan-3-yl ester;
- 10 (3-[(2-Acetylamino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid thiazol-5-ylmethyl ester;
- (6-[[2-Hydroxy-4-phenyl-3-(thiazol-5-ylmethoxycarbonylamino)-butyl]-isobutyl-sulfamoyl]-benzoxazol-2-yl)-carbamic acid ethyl ester;
- [1-Benzyl-2-hydroxy-3-((2-[(6-hydroxy-pyridine-3-carbonyl)-amino]-benzoxazole-6-sulfonyl)-isobutyl-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- 15 [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[(pyridine-3-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- (1-Benzyl-2-hydroxy-3-[isobutyl-(2-pyrrolidin-1-yl-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic acid thiazol-5-ylmethyl ester;
- 20 1-Benzyl-2-hydroxy-3-(isobutyl-(2-[methyl-(2-pyrrolidin-1-yl-ethyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- [1-Benzyl-2-hydroxy-3-(isobutyl-{2-[2-(4-methyl-piperazin-1-yl)-acetylamino]-benzoxazole-6-sulfonyl}-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- 1-Benzyl-2-hydroxy-3-(isobutyl-(2-[methyl-(5-oxo-pyrrolidine-2-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- 25 1-Benzyl-2-hydroxy-3-(isobutyl-(2-[methyl-(pyridine-4-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- 1-Benzyl-2-hydroxy-3-(isobutyl-(2-[methyl-(pyridine-3-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- 30 1-Benzyl-3-((2-[(furan-3-carbonyl)-methyl-amino]-benzoxazole-6-sulfonyl)-isobutyl-amino)-2-hydroxy-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[(1-methyl-pyrrolidine-2-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- (3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid tetrahydro-furan-3-yl ester;
- 35 (3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;

- (3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid thiazol-5-ylmethyl ester;
- (1S,2R)-3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid thiazol-5-ylmethyl ester;
- 5 (3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid pyridin-3-ylmethyl ester;
- N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(2,6-dimethyl-phenoxy)-acetamide;
- 3-Amino-N-(3-[(2-amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-
- 10 hydroxy-propyl)-2-methyl-benzamide;
- (3-[(2-Acetylamino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- (3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- 15 (1-Benzyl-3-[(2-(2-dimethylamino-ethylamino)-benzoxazole-6-sulfonyl)-isobutyl-amino]-2-hydroxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- (6-[(3-(Hexahydro-furo[2,3-b]furan-3-yloxy-carbonylamino)-2-hydroxy-4-phenyl-butyl)-isobutyl-sulfamoyl]-benzoxazol-2-yl)-carbamic acid ethyl ester;
- (1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-
- 20 propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- (1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic acid (3R,3aS,6aR)-hexahydro-furo[2,3-b]furan-3-yl ester;
- (1-Benzyl-2-hydroxy-3-(isobutyl-[2-(2-pyrrolidin-1-yl-ethylamino)-benzoxazole-6-sulfonyl]-amino)-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- 25 (1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic acid tetrahydro-furan-3-yl ester;
- (1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic acid thiazol-5-ylmethyl ester;
- N-(1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-
- 30 propyl)-3-hydroxy-2-methyl-benzamide;
- 3-Amino-N-(1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-2-methyl-benzamide;
- N-(1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-2-(2,6-dimethyl-phenoxy)-acetamide;
- 35 [6-[(3-[2-(2,6-Dimethyl-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl)-isobutyl-sulfamoyl]-benzoxazol-2-yl]-carbamic acid ethyl ester;
- N-(1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-2-(3,5-dichloro-pyridin-4-yloxy)-acetamide;

- (1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic acid hexahydro-1,7-dioxo-4-aza-inden-3-yl ester;
5-Methyl-isoxazole-4-carboxylic acid (1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-amide;
- 5 (1-Benzyl-2-hydroxy-3-[[2-(2-hydroxy-ethylamino)-benzoxazole-6-sulfonyl]-isobutyl-amino]-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
N-(1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-2-(2,6-dimethyl-4-nitro-phenoxy)-acetamide;
2-(4-Amino-2,6-dimethyl-phenoxy)-N-(1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-acetamide;
- 10 (3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid hexahydro-1,7-dioxo-4-aza-inden-3-yl ester;
N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-4-bromo-2-methyl-benzamide;
- 15 N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(4-cyano-2,6-dimethyl-phenoxy)-acetamide;
N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(2-amino-4,6-dimethyl-pyrimidin-5-yloxy)-acetamide;
(3-[(2-Amino-benzoxazole-6-sulfonyl)-pyridin-2-ylmethyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- 20 N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(4,6-dimethyl-pyrimidin-5-yloxy)-acetamide;
N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(2-amino-thiazol-4-yl)-acetamide;
- 25 (3-[(2-Amino-benzoxazole-6-sulfonyl)-pyridin-2-ylmethyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid pyridin-3-ylmethyl ester;
(3-[(2-Amino-benzoxazole-6-sulfonyl)-pyridin-2-ylmethyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid thiazol-5-ylmethyl ester;
N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-pyridin-2-ylmethyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(2,6-dimethyl-phenoxy)-acetamide;
- 30 N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-pyridin-2-ylmethyl-amino]-1-benzyl-2-hydroxy-propyl)-3-hydroxy-2-methyl-benzamide;
(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-ylmethyl ester;
- 35 (3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-2-ylmethyl ester;
N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(3,4-diamino-2,6-dimethyl-phenoxy)-acetamide;

- N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(4,6-dimethyl-1H-benzimidazol-5-yloxy)-acetamide;
N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(2,6-dimethyl-phenoxy)-4-hydroxy-butyramide;
- 5 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (3-[(2-amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-amide;
N-(1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-4-bromo-2-methyl-benzamide;
(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-
- 10 carbamic acid 3H-imidazol-4-ylmethyl ester;
(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid 2-hydroxymethyl-thiazol-4-ylmethyl ester;
N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(4-aminomethyl-2,6-dimethyl-phenoxy)-acetamide;
- 15 [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[methyl-(3-pyrrolidin-1-yl-propyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
{3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid 2-(3,5-dimethyl-pyridin-4-yloxy)-ethyl ester
- 20 [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[methyl-(2-pyrrolidin-1-yl-ethyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
(1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic acid hexahydro-1,7-dioxa-4-aza-inden-3-yl ester;
- 25 (1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic acid hexahydro-1,7-dioxa-4-aza-inden-3-yl ester;
N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-2-(3,5-dimethyl-pyridin-4-yloxy)-acetamide;
(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-
- 30 carbamic acid 3-oxo-tetrahydro-pyrrolo[1,2-c]oxazol-7-yl ester;
(1-Benzyl-2-hydroxy-3-(isobutyl-[2-(4-methyl-piperazin-1-yl)-benzoxazole-6-sulfonyl]-amino)-propyl)-carbamic acid thiazol-5-ylmethyl ester;
(1-Benzyl-3-[(2-dimethylamino-benzoxazole-6-sulfonyl)-isobutyl-amino]-2-hydroxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- 35 (6-[(2-Hydroxy-4-phenyl-3-(thiazol-5-ylmethoxycarbonylamino)-butyl]-isobutyl-sulfamoyl)-benzoxazol-2-yl)-carbamic acid methyl ester;
[1-Benzyl-2-hydroxy-3-(isobutyl-(2-[(5-oxo-pyrrolidine-2-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;

- [1-Benzyl-3-((2-[(furan-3-carbonyl)-amino]-benzoxazole-6-sulfonyl)-isobutyl-amino)-2-hydroxy-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[(1-methyl-piperidine-4-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- 5 [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[(pyridine-2-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- (3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid 2-chloro-thiazol-5-ylmethyl ester;
- (1-Benzyl-3-[(2-(2-dimethylamino-acetyl-amino)-benzoxazole-6-sulfonyl)-isobutyl-amino)-2-hydroxy-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- 10 (1-Benzyl-2-hydroxy-3-[isobutyl-(2-piperazin-1-yl-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic acid thiazol-5-ylmethyl ester;
- (1-Benzyl-2-hydroxy-3-[isobutyl-(2-piperidin-1-yl-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic acid thiazol-5-ylmethyl ester;
- 15 (1-Benzyl-2-hydroxy-3-[isobutyl-(2-(2-[methyl-(2-pyrrolidin-1-yl-ethyl)-amino]-acetyl-amino)-benzoxazole-6-sulfonyl)-amino]-propyl)-carbamic acid thiazol-5-ylmethyl ester;
- (1-Benzyl-3-[(2-dimethylamino-benzoxazole-6-sulfonyl)-isobutyl-amino]-2-hydroxy-propyl)-carbamic acid thiazol-5-ylmethyl ester;
- 20 (3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid oxazol-5-ylmethyl ester;
- [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[(pyridine-4-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[methyl-(pyridine-2-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- 25 [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[methyl-(1-methyl-piperidine-3-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[methyl-(1-methyl-piperidine-4-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- 30 [1-Benzyl-3-((2-[(2-chloro-pyridine-4-carbonyl)-methyl-amino]-benzoxazole-6-sulfonyl)-isobutyl-amino)-2-hydroxy-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- [1-Benzyl-2-hydroxy-3-(isobutyl-(2-[methyl-(1-methyl-pyrrolidine-2-carbonyl)-amino]-benzoxazole-6-sulfonyl)-amino)-propyl]-carbamic acid thiazol-5-ylmethyl ester;
- 35 N-(3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-3-hydroxy-2-methyl-4-nitro-benzamide;
- 4-Amino-N-(3-[(2-amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-3-hydroxy-2-methyl-benzamide;

- 7-Methyl-benzoxazole-6-carboxylic acid (3-[(2-amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-amide;
4-Methyl-benzo[1,3]dioxole-5-carboxylic acid (3-[(2-amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-amide;
5 (3-[(2-Amino-benzoxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl)-carbamic acid thiazol-5-ylmethyl ester;
or any stereoisomeric forms and pharmaceutically acceptable addition salts thereof.

10 Thus, the present invention also relates to HIV protease inhibitors of formula (9) or any pharmaceutically acceptable salt or prodrug thereof, obtained by using a compound of formula (6) as intermediate, wherein both compound of formula (6) and HIV protease inhibitors of formula (9) are prepared as described in the present invention.

15 The following examples are meant to illustrate the present invention. These examples are presented to exemplify the invention and are not to be considered as limiting the scope of the invention.

Examples

20 Example 1 illustrates the preparation of a benzoxazole sulfonamide compound according to the invention corresponding to formula (6) by reacting a sulfonylchloride with an intermediate corresponding to formula (5). Example 2 and 3 illustrate the preparation of 2-amino-benzoxazole sulfonamide protease inhibitors using a benzoxazole sulfonamide compound according to the invention.

25 Example 1: Preparation of a benzoxazole sulfonamide compound

A benzoxazole sulfonamide represented by compound c-6 in the below provided Scheme C, can be prepared as follows.

30 The intermediate c-2 was prepared by adding 2-mercaptobenzoxazole (c-1 which is equal to compound of formula (1) above) (1200 g; 7.94 mol) to 8500 ml ethylacetate in a 20 L flask. Then 1420 g (10.29 mol) potassium carbonate was added at rt. Iodomethane (1243 g; 8.76 mol) was added dropwise to this reaction mixture maintaining the internal temperature below 40°C. This mixture was stirred for 24 hours while the internal temperature decreased to 20°C. The reaction mixture was then
35 treated with 4000 ml water and 138 g NH₄OH at rt for about 20 minutes. The organic layer was separated and filtered. The aqueous phase was extracted with 1200 ml ethylacetate. The organic layers were collected and washed with 1500 ml water. The organic phase was evaporated under reduced pressure until a final volume of about 2000ml. Magnesium sulphate was added and the mixture was filtered. The filtrate was

evaporated under reduced pressure yielding 1288 g of the intermediate c-2 (98 % yield / HPLC purity 99.6 %).


5 In order to prepare intermediate c-3, chlorosulfonic acid (3890 g; 33.3 mol) was stirred under nitrogen. Then intermediate c-2 (1288 g; 7.80 mol) was added portionwise maintaining the internal temperature below 60°C, by external cooling. After complete addition of intermediate b-2 the reaction mixture was stirred overnight at 85°C. The heating was removed and the reaction mixture was cooled down until 65°C. SOCl₂ was added dropwise while maintaining a controlled release of gases by good stirring. This
10 mixture was stirred overnight at 65°C. This reaction mixture was added to a well stirred mixture of EtOAc (6.9 kg) and ice (9.2kg) while maintained the temperature below 0°C. The organic layer was isolated. The aqueous phase was extracted with EtOAc (3.1 kg). The combined organic layer was washed with 7.5 % NaHCO₃ (210 g/2.8 L water). Because the pH of this water layer was still 1, therefore another 125 g NaHCO₃ was
15 added. This mixture was stirred for 1 hour, then the phases were separated. The organic layer was dried with Na₂CO₃ (2.5 kg). After filtration 1935 g of intermediate c-3 was obtained (yield 94%, HPLC purity 94%) and used in the preparation of compound c-6.

Intermediate c-5 was prepared by reacting in a 20 L flask 1595 g of intermediate c-4
20 under inert conditions with 2400 g isopropanol. Then 6198 g isobutylamine was added at room temperature. The reaction mixture was heated and stirred overnight at an internal temperature of 65 °C. The excess of isobutylamine was removed as far as possible by distillation at 85°C. Then 3 L hexane was added and the solvents were removed by an azeotropic distillation at 90 °C. The azeotropic distillation with hexane
25 was repeated 3 times. The remaining product in the 20 L flask was crystallised during cooling overnight upon rt. The solid white crude was solved by adding 3 L EtOAc and heated to 65°C. After complete dissolution of the white crude, 1.5 L EtOAc was distilled. The remained solution comprising intermediate c-5 was stirred at an internal temperature of 65°C and was used *in situ* for the synthesis of compound c-6.

30 For preparing compound c-6 the solution of intermediate c-5 was stirred at >65°C and triethylamine (1400 g) was added. Then the reaction mixture was cooled to 50°C and the EtOAc solution of intermediate c-3 was added in 3 hours while maintaining the reaction-temperature at 40°C - 50°C by cooling with water. TLC showed no starting
35 material after 30 min. but the reaction was stirred overnight while the internal temperature decreased to 20°. The mixture was heated to 45°C and washed with 5 L water, with 4.2 L water plus 800 g 30% HCl and with 4.5 L water plus 250 g NaHCO₃. The organic layer was separated and crystallised by stirring overnight while the

temperature decreased to 20°C. After further cooling to 0°C - 5°C, the solid was filtered and dried in the vacuum oven at 40°C, yielding 2585 g of compound c-1 (76 % yield, HPLC purity 98.2%).

Scheme C



Example 2: Preparation of a 2-amino-benzoxazole sulfonamide (compound d-5)

- 5 This example illustrates the preparation of a 2-amino benzoxazole sulfonamide protease inhibitor, represented as d-5 in the below provided Scheme D.

For preparing this protease inhibitor intermediate d-1 was charged into a 10 L sealed reactor and heated until 105°C. The pressure rose up to 2.2 bar. Then NH₃-gas (319
10 gram; 18.7 mol NH₃-gas) was added until a pressure of 7.5 – 8 bar was achieved. This reaction mixture was stirred for 15 hours at an internal temperature of 105°C - 110°C. Then the reaction mixture was cooled to an internal temperature of 35°C and the pressure was released carefully. The reaction mixture was collected in a 10 L drum. This procedure was repeated 3 times to end up with 3 different batches (batch 1,2 and
15 3). The purity on HPLC was about 75% for the 3 different batches. The 3 different batches were collected, pooled and evaporated on a Büchi apparatus to end up with a final volume of about 6 L iso-propanol. This residue was stirred and heated at 75 °C. Water (4.5 L) was added and the slurry was stirred for 30 min at 75 °C. Then the

heating was removed and the mixture was stirred overnight at rt. The reaction mixture was filtered and washed with 400 ml iso-propanol. The product was dried for two days in the vacuum oven at 50 °C to yield 1514 gram (80% yield; HPLC purity 97.04%) of intermediate d-2.

5


Subsequently, 1514 gram of intermediate d-2, was stirred in 32 L ethylacetate and heated until 60°C. 2100 ml HCl/isopropanol 5N was added slowly and a white precipitate was formed and CO₂ gas was released. After adding all of the HCl/isopropanol 5 N the reaction mixture is stirred for 3 – 4 hours at an internal temperature of 55°C – 60 °C. Then the precipitate was filtered and washed with ethylacetate 400 ml. The wet precipitate was evaporated on a Büchi apparatus and then dried overnight in the vacuum oven at 50°C to yield 1265 gram 1 (83% yield; HPLC purity 98.58%) of intermediate d-3.

10

15 Then, intermediate d-3 was further reacted with intermediate d-4, in the presence of triethylamine and dichloromethane in order to obtain d-5, which was further purified by ethanol extraction to yield d-5 (>85 % yield / HPLC purity 97 %).

20

Scheme D



5 Example 3: Preparation of a 2-amino-benzoxazole sulfonamide (compound e-5)


This example illustrates the preparation of a 2-amino benzoxazole sulfonamide protease inhibitor, represented as e-5 in the below provided Scheme E.

A suspension of intermediate e-1 (1000 g; 1.77 mol) in 6000 ml isopropanol was heated until complete dissolution (Ti 75°C). Over a period of 5 min. methylamine (4800 g, 40%wt in H₂O; 62 mol) was added (Ti after addition 65°C). The resulting solution was
5 stirred and heated (Ti 65°C) for 1 hour. The 20 L reactor flask was opened and heated while stirring rapidly until most of excess methylamine was removed (Ti >70°C). At 70°C, 7500 ml hot water was added while maintaining the internal temperature > 70°C. Then the heating was removed and the reaction mixture was cooled to 30°C overnight. At Ti 66°C a bulky precipitate of intermediate e-2 was formed. At 30°C the precipitate
10 was filtered. The precipitate was washed with 2000 ml isopropanol/water (1/1) and dried, yielding about 1000 g of intermediate e-2 (90 - 100% yield; HPLC purity; 96.9%).

Subsequently, a suspension of 16.6kg wet intermediate e-2 was charged into a 150 L
15 reactor. Then 150 kg EtOAc was added and the suspension was stirred while heating to 78°C. The water in the reaction mixture was removed by an azeotropic distillation. The distillation was stopped when KF of the reaction mixture showed less than 0.15w/w% water. The reactor contained about 4800 g of intermediate e-2 TIC 1662 after the azeotropic distillation (± 95% yield). The remained clear solution (± 4800g
20 intermediate e-2 in 80L EtOAc) was stirred at 65°C and 6.7 L HCl/iso-propanol (5 to 6 N solution in isopropanol) was added over 0.5 hour. The resulting mixture was further stirred at an internal temperature of 65°C. Another 1 L HCl/iso-propanol (5 to 6 N solution in isopropanol) was added at 65°C. This reaction mixture was further stirred overnight while the heating was removed. The reaction mixture was cooled to 15°C
25 then filtered and washed with 5.2 kg EtOAc, yielding 8.5 kg intermediate e-3 wet, which was dried at rt under a nitrogen flow, providing 3.376 kg intermediate e-3 (74% yield; HPLC purity; 98.1%).


Then, intermediate e-3 was further reacted with intermediate e-4, in the presence of
30 triethylamine and EtOAc in order to obtain e-5 (yield 75%, purity 98.8%).

Scheme E




CLAIMS

1. A method for preparing a compound of formula (6),



(6)


and salts, stereoisomeric forms, and racemic mixtures thereof, characterized in that said method starts from a compound of formula (2),



(2)

wherein E is an electrophilic moiety;


transforming compound of formula (2) into a compound of formula (3),



(3)

wherein LG is a leaving group; and

reacting compound of formula (3) with a compound of formula (5),



(5)

wherein

PG is a protecting group;

R₂ is hydrogen or C₁₋₆alkyl;


R₃ is C₃₋₇cycloalkyl, aryl, Het¹, Het², or C₁₋₆alkyl optionally substituted with C₃₋₇cycloalkyl, aryl, Het¹, or Het²; wherein each C₃₋₇cycloalkyl, aryl, Het¹, and Het² may be optionally substituted with one or more groups selected from oxo, C₁₋₆alkyloxy, C₁₋₆alkyl,

C₁₋₆alkylsulfonyl, aminosulfonyl, amino, C₁₋₆alkylcarbonylamino, hydroxyC₁₋₆alkyl, cyano, C₁₋₆alkyloxycarbonyl, aminocarbonyl, halogen or trifluoromethyl, wherein each amino maybe mono- or disubstitued with C₁₋₆alkyl;

R₄ is selected from the group comprising hydrogen, C₁₋₄alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, or C₁₋₆alkyl optionally substituted with one or more substituents each independently selected from aryl, Het¹, Het², C₃₋₇cycloalkyl, C₁₋₄alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, C₁₋₄alkyl-S(=O)_t, hydroxy, cyano, halogen and amino optionally mono- or disubstituted where the substituents are each independently selected from C₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, Het¹, Het², Het¹C₁₋₄alkyl and Het²C₁₋₄alkyl; and


t is zero, one or two.

2. A method according to claim 1 for preparing a compound of formula (6), characterized in that said method comprises the steps of:
alkylating a compound of formula (1)



(1)


resulting into a compound of formula (2);



(2)

wherein **E** is a C₁₋₆alkyl;


reacting compound of formula (2) with a sulfonation agent, resulting in a compound of formula (3);



(3)

wherein **LG** is a leaving group; and

coupling compound of formula (3) with a compound of formula (5).




5

wherein PG is a protecting group; and


wherein R₂, R₃, and R₄ are as claimed in claim 1.

3. A method according to any one of claims 1 to 2, characterized in that compound of formula (3) is a compound of formula (3''').




15

4. A method according to any one of claims 1 to 3, characterized in that compound of formula (5) is obtained by amination of an epoxide-containing compound of formula (4), and the amination reagent is H₂N-R₄, wherein R₄ is as claimed in any one of claims 1 to 3.




20

5. A method according to any one of claims 1 to 4, wherein compound of formula (5) is compound of formula (5').



25

6. A compound having formula (6)



(6)

and salts, stereoisomeric forms, and racemic mixtures thereof, characterized in that PG, R₂, R₃, R₄, and E are as defined in any one of claims 1 to 5.

7. A compound according to claim 6, characterized in that

R₂ is hydrogen;

R₃ is arylC₁₋₄alkyl, arylmethyl, or phenylmethyl;

R₄ is unsubstituted C₁₋₆alkyl or C₁₋₆alkyl substituted with one or more substituents selected from aryl, Het¹, Het², C₃₋₇cycloalkyl and amino optionally mono- or disubstituted where the substituents are selected from C₁₋₄alkyl, aryl, Het¹ and Het².


8. A compound according to any one of claims 6 to 7, characterized in that

R₂ is hydrogen;

R₃ is phenylmethyl; and


R₄ is isobutyl.

9. A compound according to any one of claims 6 to 8, characterized in that the compound has formula (6'').




(6'')

10. A compound according to any one of claims 6 to 9, characterized in that the compound has formula (6''').



11. A compound according to any one of claims 6 to 10, characterized in that said compound is in the form of a salt selected from trifluoroacetate, fumarate, chloroacetate and methanesulfonate.

12. A method for preparing a compound of formula (9), wherein said method comprises the methods according to any one of claims 1 to 5, characterised in that said method further comprises
aminating compound of formula (6) to obtain compound of formula (7), wherein



15

R_6 is hydrogen, hydroxy, C_{1-6} alkyl, Het^1C_{1-6} alkyl, Het^2C_{1-6} alkyl, amino C_{1-6} alkyl whereby the amino group may optionally be mono- or di-substituted with C_{1-4} alkyl;

R_8 is hydrogen, C_{1-6} alkyl, or $-A-R_7$;

A is C_{1-6} alkanediyl, $-C(=O)-$, $-C(=S)-$, $-S(=O)_2-$, C_{1-6} alkanediyl- $C(=O)-$, C_{1-6} alkanediyl- $C(=S)-$ or C_{1-6} alkanediyl- $S(=O)_2-$; whereby the point of attachment to the nitrogen atom is the C_{1-6} alkanediyl group in those moieties containing said group;

R_7 is C_{1-6} alkyloxy, Het^1 , Het^1oxy , Het^2 , Het^2oxy , aryl, aryloxy, C_{3-7} cycloalkyl, or optionally mono- or disubstituted amino; and


in case $-A-$ is other than C_{1-6} alkanediyl then R_7 may also be C_{1-6} alkyl, Het^1C_{1-4} alkyl, Het^1oxyC_{1-4} alkyl, Het^2C_{1-4} alkyl, Het^2oxyC_{1-4} alkyl, aryl C_{1-4} alkyl, aryloxy C_{1-4} alkyl or amino- C_{1-6} alkyl; whereby each of the amino groups in the definition of R_7 may optionally be substituted with one or more substituents selected from C_{1-4} alkyl, C_{1-4} alkylcarbonyl, C_{1-4} alkyloxycarbonyl, aryl, arylcarbonyl, aryloxycarbonyl, Het^1 , Het^2 , aryl C_{1-4} alkyl, Het^1-C_{1-4} alkyl or Het^2C_{1-4} alkyl; and

$-A-R_7$ may also be hydroxy C_{1-6} alkyl; and

30


R_6 and $-A-R_7$ taken together with the nitrogen atom to which they are attached may also form Het^1 or Het^2 ;

deprotecting compound of formula (7) to obtain compound of formula (8),



(8)


coupling a radical of formula R_1-L to obtain compound of formula (9),



(9)

and N -oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein

R_1 is selected from the group comprising hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, aryl C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkyl, aryl, Het^1 , Het^1C_{1-6} alkyl, Het^2 , Het^2C_{1-6} alkyl; and R_1 may also be a radical of formula (10)



(10)

R_9 , R_{10a} and R_{10b} are, each independently, hydrogen, C_{1-4} alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyl, C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{1-4} alkyl optionally substituted with aryl, Het^1 , Het^2 , C_{3-7} cycloalkyl, C_{1-4} alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C_{1-4} alkyl)-aminocarbonyl, aminosulfonyl, C_{1-4} alkylS(O)_n, hydroxy, cyano, halogen or amino optionally mono- or disubstituted where the substituents are each independently selected from C_{1-4} alkyl, aryl, aryl C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, Het^1 , Het^2 , Het^1C_{1-4} alkyl and

Het²C₁₋₄alkyl; whereby R₉, R_{10a} and the carbon atoms to which they are attached may also form a C₃₋₇cycloalkyl radical;

when L is -O-C₁₋₆alkanediyl-C(=O)- or -NR₁₂-C₁₋₆alkanediyl-C(=O)-, then R₉ may also be oxo;

- 5 R_{11a} is selected from the group comprising hydrogen, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, aryl, aminocarbonyl optionally mono- or disubstituted, aminoC₁₋₄alkylcarbonyloxy optionally mono- or disubstituted, C₁₋₄alkyloxycarbonyl, aryloxycarbonyl, Het¹oxycarbonyl, Het²oxycarbonyl, aryloxycarbonylC₁₋₄alkyl, arylC₁₋₄alkyloxycarbonyl, C₁₋₄alkylcarbonyl, C₃₋₇cycloalkylcarbonyl, C₃₋₇cycloalkyl-
10 C₁₋₄alkyloxycarbonyl, C₃₋₇cycloalkylcarbonyloxy, carboxylC₁₋₄alkylcarbonyloxy, C₁₋₄alkylcarbonyloxy, arylC₁₋₄alkylcarbonyloxy, arylcarbonyloxy, aryloxycarbonyloxy, Het¹carbonyl, Het¹carbonyloxy, Het¹C₁₋₄alkyloxycarbonyl, Het²carbonyloxy, Het²C₁₋₄alkylcarbonyloxy, Het²C₁₋₄alkyloxycarbonyloxy or C₁₋₄alkyl optionally substituted with aryl, aryloxy, Het² or hydroxy; wherein the substituents on the amino
15 groups are each independently selected from C₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl C₁₋₄alkyl, Het¹, Het², Het¹C₁₋₄alkyl and Het²C₁₋₄alkyl;

- R_{11b} is selected from the group comprising hydrogen, C₃₋₇cycloalkyl, C₂₋₆alkenyl,
20 C₂₋₆alkynyl, aryl, Het¹, Het² or C₁₋₄alkyl optionally substituted with halogen, hydroxy, C₁₋₄alkylS(=O)₁, aryl, C₃₋₇cycloalkyl, Het¹, Het², amino optionally mono- or disubstituted where the substituents are each independently selected from C₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, Het¹, Het², Het¹C₁₋₄alkyl and Het²C₁₋₄alkyl;

- 25 whereby R_{11b} may be linked to the remainder of the molecule via a sulfonyl group; and

- L is selected from the group comprising -C(=O)-, -O-C(=O)-, -NR₁₂-C(=O)-, -O-C₁₋₆alkanediyl-C(=O)-, -NR₁₂-C₁₋₆alkanediyl-C(=O)-, -S(=O)₂-, -O-S(=O)₂-, -NR₁₂-S(=O)₂ whereby either the C(=O) group or the S(=O)₂ group is attached to the
30 NR₂ moiety; whereby the C₁₋₆alkanediyl moiety is optionally substituted with a substituent selected from hydroxy, aryl, Het¹, and Het²;

R₁₂ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, arylC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, aryl, Het¹, Het¹C₁₋₆alkyl, Het², Het²C₁₋₆alkyl;

R₂ is hydrogen or C₁₋₆alkyl;

- 35 R₃ is C₃₋₇cycloalkyl, aryl, Het¹, Het², or C₁₋₆alkyl optionally substituted with C₃₋₇cycloalkyl, aryl, Het¹, or Het²; wherein each C₃₋₇cycloalkyl, aryl, Het¹, and Het² may be optionally substituted with one or more groups selected from oxo, C₁₋₆alkyloxy, C₁₋₆alkyl,


C₁₋₆alkylsulfonyl, aminosulfonyl, amino, C₁₋₆alkylcarbonylamino, hydroxyC₁₋₆alkyl, cyano, C₁₋₆alkyloxycarbonyl, aminocarbonyl, halogen or trifluoromethyl, wherein each amino maybe mono- or disubstitued with C₁₋₆alkyl;

R₄ is selected from the group comprising hydrogen, C₁₋₄alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, or C₁₋₆alkyl optionally substituted with one or more substituents each independently selected from aryl, Het¹, Het², C₃₋₇cycloalkyl, C₁₋₄alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, C₁₋₄alkyl-S(=O)_t, hydroxy, cyano, halogen and amino optionally mono- or disubstitued where the substituents are each independently selected from C₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, Het¹, Het², Het¹C₁₋₄alkyl and Het²C₁₋₄alkyl; and

t is zero, one or two.

13. The method according to claim 12, wherein

R₁ is a radical of formula (10)



(10)

20

R₉, R_{10a} and R_{10b} are, each independently, hydrogen, C₁₋₄alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl or C₁₋₄alkyl optionally substituted with aryl, Het¹, Het², C₃₋₇cycloalkyl, C₁₋₄alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)-aminocarbonyl, aminosulfonyl, C₁₋₄alkylS(O)_t, hydroxy, cyano, halogen or amino optionally mono- or disubstitued where the substituents are each independently selected from C₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, Het¹, Het², Het¹C₁₋₄alkyl and Het²C₁₋₄alkyl;

whereby R₉, R_{10a} and the carbon atoms to which they are attached may also form a C₃₋₇cycloalkyl radical;

R_{11b} is hydrogen, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, aryl, Het¹, Het² or C₁₋₄alkyl optionally substituted with halogen, hydroxy, C₁₋₄alkylS(=O)_t, aryl, C₃₋₇cycloalkyl, Het¹, Het², amino optionally mono- or disubstitued where the

substituents are each independently selected from C₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, Het¹, Het², Het¹C₁₋₄alkyl and Het²C₁₋₄alkyl; whereby R_{11b} may be linked to the remainder of the molecule via a sulfonyl group;

5 t is zero, one or two;

L is -C(=O)-, -O-C(=O)-, -NR₁₂-C(=O)-, -O-C₁₋₆alkanediyl-C(=O)-, -NR₁₂-C₁₋₆alkanediyl-C(=O)-, -S(=O)₂-, -O-S(=O)₂-, -NR₁₂-S(=O)₂ whereby either the C(=O) group or the S(=O)₂ group is attached to the NR₂ moiety; whereby the C₁₋₆alkanediyl moiety is optionally substituted with a substituent selected from hydroxy, aryl, Het¹, and Het²;

10 R₁₂ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, arylC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, aryl, Het¹, Het¹C₁₋₆alkyl, Het², Het²C₁₋₆alkyl; and

R₄ is hydrogen, C₁₋₄alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, or C₁₋₆alkyl optionally substituted with one or more substituents selected from aryl, Het¹, Het², C₃₋₇cycloalkyl, C₁₋₄alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, C₁₋₄alkylS(=O)_n, hydroxy, cyano, halogen and amino optionally mono- or disubstituted where the substituents are selected from C₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, Het¹, Het², Het¹C₁₋₄alkyl and Het²C₁₋₄alkyl.

14. The method according to any one of claims 12 to 13, wherein one or more of the following restrictions apply:

25 R₁ is hydrogen, Het¹, Het², aryl, Het¹C₁₋₆alkyl, Het²C₁₋₆alkyl, arylC₁₋₆alkyl, more in particular, R₁ is a saturated or partially unsaturated monocyclic or bicyclic heterocycle having 5 to 8 ring members, which contains one or more heteroatom ring members selected from nitrogen, oxygen or sulfur and which is optionally substituted, or phenyl optionally substituted with one or more substituents;

R₂ is hydrogen;

30 L is -C(=O)-, -O-C(=O)-, -O-C₁₋₆alkanediyl-C(=O)-, more in particular, L is -O-C(=O)- or -O-C₁₋₆alkanediyl-C(=O)-, whereby in each case the C(=O) group is attached to the NR₂ moiety;

R₃ is arylC₁₋₄alkyl, in particular, arylmethyl, more in particular phenylmethyl;

35 R₄ is optionally substituted C₁₋₆alkyl, in particular unsubstituted C₁₋₆alkyl or C₁₋₆alkyl optionally substituted with one or more substituents selected from aryl, Het¹, Het², C₃₋₇cycloalkyl and amino optionally mono- or disubstituted where the substituents are selected from C₁₋₄alkyl, aryl, Het¹ and Het²;

R₆ is hydrogen or methyl; and

R_8 is hydrogen or methyl.

15. The method according to any one of claims 12 to 14, wherein

R_1-L is $Het^1-O-C(=O)$, $Het^2-C_{1-6}alkanediy-O-C(=O)$, aryl- $O-C_{1-6}alkanediy-$
5 $C(=O)$ or aryl- $C(=O)$.

16. The method according to any one of claims 12 to 15, wherein

NR_6R_8 is amino, monomethylamino or dimethylamino.

10 17. The method according to to any one of claims 12 to 16, wherein

R_1 is a Het^1 , or a $Het^1C_{1-6}alkyl$, and

L is $-O-C(=O)-$;

R_2 is hydrogen;

R_3 is phenylmethyl;


15 R_4 is isobutyl;

R_6 is hydrogen; and

R_8 is hydrogen or methyl.

18. The method according to any one of claims 12 to 17, wherein compound (9) has

20 formula (9''').



19. The method according to any one of claims 12 to 18, characterized in that
25 compound of formula (9) is in the form of a salt selected from trifluoroacetate,
fumarate, chloroacetate and methanesulfonate.

20. Use of a compound as claimed in any of claims 7 to 11 as an intermediate for
preparing a retrovirus protease inhibitor of formula (9).

Abstract**5 METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE
 COMPOUNDS AND INTERMEDIATES THEREOF**

The present invention relates to methods for the preparation of benzoxazole sulfonamide compounds as well as novel intermediates for use in said method. More in particular the invention relates to methods for the preparation of 2-amino-benzoxazole sulfonamide compounds which make use of 2-mercapto-benzoxazole sulfonamide intermediates, more in particular methods employing the intermediate 1-Benzyl-2-hydroxy-3-[isobutyl-(2-methylsulfanyl-benzoxazole-6-sulfonyl)-amino]-propyl-carbamic ester, and to methods amenable to industrial scaling up. Said benzoxazole sulfonamide compounds are particularly useful as HIV protease inhibitors.

10

15

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.